Doxorubicin (Synonyms: Hydroxydaunorubicin)

Cat. No.: HY-15142A: Data Sheet Handling Instructions
FAQs
Technical Support

Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy. Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM.

For research use only. We do not sell to patients.

Doxorubicin Chemical Structure

CAS No. : 23214-92-8

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Doxorubicin:

Doxorubicin hydrochloride

Other Forms of Doxorubicin:

Doxorubicin hydrochloride In-stock
Doxorubicin-¹³C,d₃ TFA Get quote

476 Publications Citing Use of MCE Doxorubicin

IHC

Cell Viability Assay

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 May 9;23(1):83. [Abstract]; Exhausted T-cells (NExT) loaded with Doxorubicin (5–50 nM; 48 h) significantly reduces the viability of SUM159 cells.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398. [Abstract]; Doxorubicin hydrochloride (10 μM; 3-5 days) significantly reduces the viability of lung cancer organoid-2 (LCO-2) and LCO-3, while showing no significant effect on LCO-1 viability.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 23 October 2021.; Cell viability after incubated with free DOX under normoxia and hypoxia at various DOX (Doxorubicin) (0.65-20 μg/mL) concentrations for 24 h determined by MTT assay.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2020 Sep;22(9):1056-1063. [Abstract]; UFMylation of endogenous p53 was analysed by western blot in HCT116 p53+/+ cells depleted of UFL1 or DDRGK1 upon DNA damage induced by doxorubicin (doxo; 1 µM; 24 h) or etoposide (eto; 25 µg ml−1; 12 h).

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]; Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]; Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2019 Jan;130:557-567. [Abstract]; Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047. [Abstract]; Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139. [Abstract]; One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499. [Abstract]; Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

: Doxorubicin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232. [Abstract]; Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350. [Abstract]; HY-15142

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973. [Abstract]; U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Med. 2016 May;22(5):547-56. [Abstract]; Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

View All Isoforms

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

View All AMPK Isoform Specific Products:

View All Isoforms

NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy^[1]^[2]. Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM^[3].

IC₅₀ & Target^[1]^[2]^[3]^[7]

Topoisomerase I

0.8 μM (IC₅₀)

Topoisomerase II

2.67 μM (IC₅₀)

Daunorubicins/Doxorubicins

HIV-1

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
16HBE14o-	GI₅₀	0.18 μM Compound: Adriamycin	Growth inhibition of human 16HBE cells by sulforhodamine B assay Growth inhibition of human 16HBE cells by sulforhodamine B assay	[PMID: 24650643]
184B5	GI₅₀	1.15 μM Compound: Doxorubicin	Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
184B5	GI₅₀	1.2 μM Compound: Doxorubicin	Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay	[PMID: 30071406]
1A9	EC₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human 1A9 cells after 72 hrs Cytotoxicity against human 1A9 cells after 72 hrs	[PMID: 17378530]
3Y1 cell line	GI₅₀	3.8 nM Compound: adriamycin	Cytotoxicity against rat 3Y1 cells after 72 hrs by MTT assay Cytotoxicity against rat 3Y1 cells after 72 hrs by MTT assay	[PMID: 10691710]
4T1	IC₅₀	0.481 μM Compound: Doxorubicin	Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
4T1	IC₅₀	0.99 μM Compound: Doxorubicin	Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
4T1	IC₅₀	90 nM Compound: Doxorubicin	Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 35213166]
5637	IC₅₀	0.02 μM Compound: doxo	Antiproliferative activity against human 5637 cell line by MTT assay Antiproliferative activity against human 5637 cell line by MTT assay	[PMID: 16913700]
5-8F	IC₅₀	0.34 μM Compound: DOX	Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36709571]
769-P	IC₅₀	0.45 μM Compound: Doxorubicin	Anticancer activity against human 769-P cells by MTT assay Anticancer activity against human 769-P cells by MTT assay	[PMID: 31404864]
786-0	GI₅₀	< 0.046 μM Compound: Dox	Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
786-0	GI₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human 786-0 cells by sulforhodamine B assay Cytotoxicity against human 786-0 cells by sulforhodamine B assay	[PMID: 26913941]
786-0	GI₅₀	0.025 μg/mL Compound: DOX; Doxo	Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay	[PMID: 26859070]
786-0	GI₅₀	0.04 μg/mL Compound: DOX	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
786-0	GI₅₀	0.11 μM Compound: Dox	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
786-0	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay	[PMID: 24824796]
786-0	GI₅₀	0.13 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay	[PMID: 23871905]
786-0	GI₅₀	0.13 μM Compound: Doxorubicin	Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
786-0	GI₅₀	0.13 μM Compound: Doxorubicin	Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
786-0	GI₅₀	0.15 μg/mL Compound: Doxorubicin	Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26561866]
786-0	GI₅₀	0.15 μg/mL Compound: DOX	Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
786-0	GI₅₀	0.15 μM Compound: DOXO	Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
786-0	GI₅₀	0.16 μM Compound: Doxorubicin	Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 33477019]
786-0	GI₅₀	0.18 μg/mL Compound: Doxorubicin	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 22410248]
A 172	IC₅₀	0.13 μM Compound: DOX	Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 34968902]
A 172	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human A172 cells after 72 hrs by MTT assay Cytotoxicity against human A172 cells after 72 hrs by MTT assay	[PMID: 30659997]
A204	IC₅₀	0.006482 μM Compound: Doxorubicin	Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay	[PMID: 30540463]
A2058	CC₅₀	1.79 μM Compound: Doxorubicin	Cytotoxicity against human A2058 cells after 72 hrs by MTT assay Cytotoxicity against human A2058 cells after 72 hrs by MTT assay	[PMID: 29792325]
A2058	EC₅₀	6.5 μM Compound: 12	Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 29172528]
A2780	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by SRB assay Cytotoxicity against human A2780 cells after 48 hrs by SRB assay	[PMID: 20673627]
A2780	GI₅₀	< 0.1 μM Compound: ADR	Anticancer activity against human A2780 cells by SRB method Anticancer activity against human A2780 cells by SRB method	[PMID: 22104151]
A2780	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
A2780	IC₅₀	0.0096 μM Compound: Doxirubicin	Concentration required to inhibit A2780-cell growth by 50% Concentration required to inhibit A2780-cell growth by 50%	[PMID: 9703471]
A2780	EC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
A2780	EC₅₀	0.01 μM Compound: DR	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
A2780	IC₅₀	0.01 μM Compound: DX	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
A2780	IC₅₀	0.02 μM Compound: doxorubicin	Antiproliferative activity against human A2780 cells after 3 days by MTT assay Antiproliferative activity against human A2780 cells after 3 days by MTT assay	[PMID: 19093883]
A2780	IC₅₀	0.044 μM Compound: Doxorubicin	Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry	[PMID: 21354800]
A2780	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33823396]
A2780	IC₅₀	0.1 μM Compound: adriamycin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 17190442]
A2780	IC₅₀	0.123 μM Compound: Dox	Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30599418]
A2780	GI₅₀	0.16 μM Compound: ADR	Growth inhibition of human A2780 cells after 48 hrs by SRB assay Growth inhibition of human A2780 cells after 48 hrs by SRB assay	[PMID: 20031423]
A2780	GI₅₀	0.16 μM Compound: ADR	Growth inhibition of human A2780 cells by SRB assay Growth inhibition of human A2780 cells by SRB assay	[PMID: 22361684]
A2780	GI₅₀	0.16 μM Compound: ADR	Anticancer activity against human A2780 cells by SRB method Anticancer activity against human A2780 cells by SRB method	[PMID: 21676506]
A2780	GI₅₀	0.16 μM Compound: ADR	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
A2780	GI₅₀	0.16 μM Compound: ADR	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
A2780	GI₅₀	0.16 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
A2780	GI₅₀	0.16 μM Compound: ADR	Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
A2780	GI₅₀	0.17 μM Compound: adriamycin	Cytotoxicity against human A2780 cells after 24 hrs by SRB method Cytotoxicity against human A2780 cells after 24 hrs by SRB method	[PMID: 18262426]
A2780	GI₅₀	0.17 μM Compound: ADR, Adriamycin	Growth inhibition of human A2780 cells by SRB method Growth inhibition of human A2780 cells by SRB method	[PMID: 18207392]
A2780	IC₅₀	0.18 μM Compound: ADM; DOX	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
A2780	IC₅₀	0.27 μM Compound: DOX	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 26386603]
A2780	IC₅₀	0.33 μM Compound: Adriamycin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 22070654]
A2780	IC₅₀	0.5 μM Compound: ADR	Cytotoxicity against human A2780 cells by SRB assay Cytotoxicity against human A2780 cells by SRB assay	[PMID: 18656370]
A2780	IC₅₀	0.5 μM Compound: ADR	Cytotoxicity against human A2780 cells by sulforhodamine B assay Cytotoxicity against human A2780 cells by sulforhodamine B assay	[PMID: 17822905]
A2780	IC₅₀	0.6 μM Compound: Doxorubicin	Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay	[PMID: 33348171]
A2780	IC₅₀	0.6 μM Compound: Adriamycin	Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26356746]
A2780	IC₅₀	0.71 μM Compound: DOX	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
A2780	IC₅₀	0.98 μM Compound: DOX	Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
A2780	IC₅₀	1.3 μM Compound: Doxorubicin	Cytotoxicity against human A2780 cells after 24 hrs by MTT assay Cytotoxicity against human A2780 cells after 24 hrs by MTT assay	[PMID: 26252628]
A2780	IC₅₀	1.9 μM Compound: DOX	Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method	[PMID: 25061803]
A2780	IC₅₀	23 nM Compound: doxorubicin	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23886686]
A-375	EC₅₀	0.009 μM Compound: Doxorubicin	Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis	[PMID: 33859796]
A-375	EC₅₀	0.009 μM Compound: Dox	Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay	[PMID: 33268144]
A-375	IC₅₀	0.01 μM Compound: doxorubicin	Cytotoxicity against human A375 cells after 24 hrs by MTT assay Cytotoxicity against human A375 cells after 24 hrs by MTT assay	[PMID: 18281125]
A-375	IC₅₀	0.01 μM Compound: doxorubicin	Cytotoxicity against human A375 cells after 24 hrs by MTT assay Cytotoxicity against human A375 cells after 24 hrs by MTT assay	[PMID: 17400463]
A-375	IC₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
A-375	IC₅₀	0.024 μM Compound: Doxorubicin	Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A-375	IC₅₀	0.13 μM Compound: DOX	Antiproliferative activity against human A375 cells after 72 hrs by MTT assay Antiproliferative activity against human A375 cells after 72 hrs by MTT assay	[PMID: 21496972]
A-375	IC₅₀	0.19 μM Compound: ADM; DOX	Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
A-375	IC₅₀	0.26 μM Compound: DOX	Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
A-375	IC₅₀	0.33 μM Compound: DOX	Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 35818137]
A-375	IC₅₀	0.37 μM Compound: DOX	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
A-375	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
A-375	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay	[PMID: 35271771]
A-375	IC₅₀	0.75 μM Compound: ADM	Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A-375	IC₅₀	1 μM Compound: ADM	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 26280921]
A-375	IC₅₀	1 μM Compound: ADM	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 25874331]
A-375	IC₅₀	1.2 μM Compound: Doxorubicin	Anticancer activity against human A375 cells by MTT assay Anticancer activity against human A375 cells by MTT assay	10.1039/C4MD00219A
A-375	IC₅₀	1.8 μg/mL Compound: doxorubicin	Cytotoxicity against human A375 cells after 24 hrs by MTT assay Cytotoxicity against human A375 cells after 24 hrs by MTT assay	[PMID: 12608856]
A-375	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32975117]
A-375	IC₅₀	5.51 μM Compound: Doxorubicin	Anticancer activity against human A375 cells after 48 hrs by MTT assay Anticancer activity against human A375 cells after 48 hrs by MTT assay	[PMID: 22136907]
A-375	IC₅₀	6.35 μM Compound: Dox	Antiproliferative activity against human A375 cells for 24 hrs by MTT assay Antiproliferative activity against human A375 cells for 24 hrs by MTT assay	[PMID: 24929289]
A-375	IC₅₀	7.01 μM Compound: Doxorubicin	Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay	[PMID: 30433783]
A-375	IC₅₀	7.2 μM Compound: Doxo	Cytotoxicity against human A375 cells after 48 hrs by MTT assay Cytotoxicity against human A375 cells after 48 hrs by MTT assay	[PMID: 25563891]
A-431	GI₅₀	0.0012 μM Compound: Doxorubicin	Antiproliferative activity against human A431 cells by SRB assay Antiproliferative activity against human A431 cells by SRB assay	[PMID: 19394218]
A-431	IC₅₀	0.03 μM Compound: Dox	Anticancer activity against human A431 cells after 48 hrs by MTT assay Anticancer activity against human A431 cells after 48 hrs by MTT assay	[PMID: 22209733]
A-431	IC₅₀	0.05 μM Compound: adriamycin	Growth inhibition of human A431 cells by MTT assay Growth inhibition of human A431 cells by MTT assay	[PMID: 17049252]
A-431	IC₅₀	0.16 μM Compound: DOX	Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
A-431	GI₅₀	0.18 μM Compound: Doxorubicin	Growth inhibition of human A431 cells after 2 days by SRB assay Growth inhibition of human A431 cells after 2 days by SRB assay	[PMID: 22000924]
A-431	GI₅₀	0.18 μM Compound: Doxorubicine	Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay	[PMID: 20045222]
A-431	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 18692939]
A-431	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human A431 cells after 48 hrs by MTT assay Cytotoxicity against human A431 cells after 48 hrs by MTT assay	[PMID: 20846862]
A-431	EC₅₀	0.7 μM Compound: Doxorubicin	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35567964]
A-431	ED₅₀	1.2 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human A431 cells by MTT assay Cytotoxicity against human A431 cells by MTT assay	[PMID: 7714533]
A-431	IC₅₀	1.35 nM Compound: DOX	Cytotoxicity against human A431 cells by SRB assay Cytotoxicity against human A431 cells by SRB assay	[PMID: 24890652]
A-431	IC₅₀	1.43 μM Compound: Doxorubicin	Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
A498	ED₅₀	0.00286 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 11087592]
A498	ED₅₀	0.0156 μg/mL Compound: adriamycin	Cytotoxicity against human A-498 cells after 7 days by MTT assay Cytotoxicity against human A-498 cells after 7 days by MTT assay	[PMID: 10514307]
A498	IC₅₀	0.035 μM Compound: adriamycin	Antitumor activity against human A498 cells by methylene blue staining method Antitumor activity against human A498 cells by methylene blue staining method	[PMID: 17656091]
A498	GI₅₀	0.1 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human A498 cells after 48 hrs by SRB assay Cytotoxicity against human A498 cells after 48 hrs by SRB assay	[PMID: 23871905]
A498	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
A498	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
A498	ED₅₀	1 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9214729]
A498	ED₅₀	1 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8882434]
A498	ED₅₀	1.1 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	10.1021/np970510f
A498	IC₅₀	1.1 μM Compound: Doxorubicin	Antiproliferative activity against human A498 cells after 48 hrs by SRB assay Antiproliferative activity against human A498 cells after 48 hrs by SRB assay	[PMID: 30503942]
A498	ED₅₀	1.13 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9322367]
A498	ED₅₀	1.22 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9134750]
A498	ED₅₀	1.58 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9584396]
A498	ED₅₀	1.78 ng/mL Compound: Adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8946743]
A498	ED₅₀	1.9 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 10395501]
A498	ED₅₀	1.9 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A-498 cells by MTT assay Cytotoxicity against human A-498 cells by MTT assay	[PMID: 9917277]
A498	ED₅₀	1.97 ng/mL Compound: Adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 7494147]
A498	ED₅₀	1.98 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9599253]
A498	ED₅₀	2.26 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 11325235]
A498	ED₅₀	2.86 ng/mL Compound: adriamycin	Cytotoxicity against human A-498 cells after 7 days by MTT assay Cytotoxicity against human A-498 cells after 7 days by MTT assay	[PMID: 15730242]
A498	ED₅₀	3.2 ng/mL Compound: Adriamycin	Cytotoxicity against human A498 cells by MTT assay Cytotoxicity against human A498 cells by MTT assay	[PMID: 7714533]
A498	ED₅₀	3.66 x 10^-4 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8676130]
A498	ED₅₀	4.24 ng/mL Compound: adr	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9461654]
A498	IC₅₀	4.9 ng/mL Compound: Adriamycin	Cytotoxicity against human A498 cells by MTT assay Cytotoxicity against human A498 cells by MTT assay	[PMID: 9644064]
A498	IC₅₀	6.1 μM Compound: DOX	Antiproliferative activity against human A498 cells after 72 hrs by MTT assay Antiproliferative activity against human A498 cells after 72 hrs by MTT assay	[PMID: 30429098]
A498	ED₅₀	6.2 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9599260]
A498	ED₅₀	6.49 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8904848]
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	10.1039/C6MD00097E
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition in human A549 cells after 48 hrs by SRB assay Growth inhibition in human A549 cells after 48 hrs by SRB assay	[PMID: 31546197]
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 26994690]
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 26067381]
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 25827522]
A549	IC₅₀	< 0.1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22330634]
A549	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
A549	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay	10.1007/s00044-011-9884-x
A549	GI₅₀	< 1 μM Compound: DOX	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31990554]
A549	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 33847126]
A549	IC₅₀	> 100 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33340938]
A549	ED₅₀	0.001 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 19783438]
A549	ED₅₀	0.001 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by sulforhodamine B method Cytotoxicity against human A549 cells by sulforhodamine B method	[PMID: 12193011]
A549	IC₅₀	0.001 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 22951040]
A549	IC₅₀	0.0014 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by sulforhodamine B bioassay Cytotoxicity against human A549 cells by sulforhodamine B bioassay	[PMID: 25098650]
A549	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
A549	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 25466198]
A549	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 22483395]
A549	GI₅₀	0.003 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells by SRB assay Antiproliferative activity against human A549 cells by SRB assay	[PMID: 19394218]
A549	IC₅₀	0.004 μM Compound: Doxorubicin	Inhibitory activity against A549 cell line using MTT assay(Wild type p53) Inhibitory activity against A549 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
A549	ED₅₀	0.0043 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 10514307]
A549	ED₅₀	0.00622 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 11087592]
A549	GI₅₀	0.007 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 19405508]
A549	IC₅₀	0.007 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 19435339]
A549	ED₅₀	0.007 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 18314958]
A549	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
A549	ED₅₀	0.01 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 15921415]
A549	IC₅₀	0.01 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 21684168]
A549	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20719504]
A549	ED₅₀	0.012 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB method Cytotoxicity against human A549 cells by SRB method	[PMID: 16252909]
A549	IC₅₀	0.015 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27668963]
A549	GI₅₀	0.016 μM Compound: Doxorubicin	Cytostatic activity against human A549 cells after 5 days by SRB assay Cytostatic activity against human A549 cells after 5 days by SRB assay	[PMID: 21711054]
A549	ED₅₀	0.02 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 15730260]
A549	ED₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 11325244]
A549	IC₅₀	0.02 μg/mL Compound: doxorubicin	Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time	[PMID: 8496904]
A549	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay	[PMID: 23634786]
A549	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 23815260]
A549	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
A549	IC₅₀	0.02 μM Compound: 2	Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation	10.1016/S0960-894X(97)10122-6
A549	IC₅₀	0.021 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay	[PMID: 27856237]
A549	IC₅₀	0.021 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20594848]
A549	IC₅₀	0.022 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 18321715]
A549	IC₅₀	0.025 μg/mL Compound: ADR	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18590312]
A549	IC₅₀	0.025 μM Compound: adriamycin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 19028425]
A549	ED₅₀	0.03 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 24 hrs by SRB assay Cytotoxicity against human A549 cells after 24 hrs by SRB assay	[PMID: 20850305]
A549	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
A549	IC₅₀	0.031 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by SRB method Cytotoxicity against human A549 cells after 24 hrs by SRB method	[PMID: 18429610]
A549	GI₅₀	0.04 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 11000028]
A549	IC₅₀	0.04 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 15921426]
A549	IC₅₀	0.04 μg/mL Compound: doxorubicin	Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 19342127]
A549	IC₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay	[PMID: 25534608]
A549	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29275232]
A549	IC₅₀	0.04 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay	[PMID: 35255689]
A549	IC₅₀	0.049 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 23544451]
A549	ED₅₀	0.05 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	10.1021/np960188t
A549	IC₅₀	0.05 μg/mL Compound: doxorubicin	Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time	[PMID: 8496904]
A549	IC₅₀	0.056 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay	[PMID: 32755677]
A549	IC₅₀	0.057 μg/mL Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
A549	GI₅₀	0.06 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay	[PMID: 23871905]
A549	GI₅₀	0.06 μM Compound: Doxorubicin	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
A549	GI₅₀	0.06 μM Compound: Doxorubicin	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
A549	GI₅₀	0.062 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 20014800]
A549	GI₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 24158013]
A549	IC₅₀	0.074 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31999451]
A549	IC₅₀	0.075 μM Compound: Doxorubicin	Anticancer activity against human A549 cells by sulforhodamine B assay Anticancer activity against human A549 cells by sulforhodamine B assay	[PMID: 19819696]
A549	IC₅₀	0.08 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19361894]
A549	IC₅₀	0.08 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30106296]
A549	IC₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27060757]
A549	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay	10.1007/s00044-010-9517-9
A549	IC₅₀	0.09 μM Compound: Dox	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34116381]
A549	IC₅₀	0.092 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 32432867]
A549	ED₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 16252910]
A549	IC₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
A549	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 28398051]
A549	IC₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 24050254]
A549	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 18063366]
A549	GI₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 19007287]
A549	GI₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 17512741]
A549	IC₅₀	0.1 μM Compound: DOX	Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction) Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)	10.1016/S0960-894X(01)81264-6
A549	IC₅₀	0.11 μM Compound: DOX	Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
A549	IC₅₀	0.118 μM Compound: Doxorubicin	Anticancer activity against human A549 cells after 48 hrs by SRB assay Anticancer activity against human A549 cells after 48 hrs by SRB assay	[PMID: 17070967]
A549	ED₅₀	0.12 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 9392887]
A549	IC₅₀	0.12 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27886545]
A549	IC₅₀	0.12 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 17673337]
A549	IC₅₀	0.124 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25462279]
A549	IC₅₀	0.124 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 28139925]
A549	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay	[PMID: 34119830]
A549	IC₅₀	0.13 μM Compound: DOX	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 30106296]
A549	IC₅₀	0.14 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35694689]
A549	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26280922]
A549	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 26873414]
A549	GI₅₀	0.15 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 20673627]
A549	IC₅₀	0.15 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 17194596]
A549	IC₅₀	0.16 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 24 hrs by SRB assay Cytotoxicity against human A549 cells after 24 hrs by SRB assay	[PMID: 24370114]
A549	GI₅₀	0.16 μM Compound: Doxorubicin	Growth inhibition of human A549 cells after 72 hrs by SRB assay Growth inhibition of human A549 cells after 72 hrs by SRB assay	[PMID: 18585035]
A549	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20176479]
A549	IC₅₀	0.17 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 6 days by MTT method Cytotoxicity against human A549 cells after 6 days by MTT method	[PMID: 16309317]
A549	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30902399]
A549	IC₅₀	0.17 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 20593838]
A549	IC₅₀	0.18 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB microtiter plate assay Cytotoxicity against human A549 cells by SRB microtiter plate assay	[PMID: 17585747]
A549	IC₅₀	0.19 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 15387653]
A549	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by XTT assay Cytotoxicity against human A549 cells after 24 hrs by XTT assay	[PMID: 27227682]
A549	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 18973388]
A549	IC₅₀	0.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT colorimetric method Cytotoxicity against human A549 cells by MTT colorimetric method	[PMID: 17125220]
A549	IC₅₀	0.2 μM Compound: adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17190442]
A549	GI₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 29112820]
A549	ED₅₀	0.21 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17315955]
A549	IC₅₀	0.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTS assay Cytotoxicity against human A549 cells after 24 hrs by MTS assay	[PMID: 30289713]
A549	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 24852278]
A549	IC₅₀	0.22 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells by MTT reduction assay Antiproliferative activity against human A549 cells by MTT reduction assay	[PMID: 33421712]
A549	IC₅₀	0.223 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay	[PMID: 29409753]
A549	IC₅₀	0.23 μM Compound: Doxo	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	[PMID: 27036521]
A549	IC₅₀	0.24 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay	[PMID: 31679979]
A549	IC₅₀	0.258 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25019480]
A549	IC₅₀	0.27 μg/mL Compound: Doxorubicin	Cytotoxic activity against human A549 cells by MTT assay Cytotoxic activity against human A549 cells by MTT assay	[PMID: 28366267]
A549	GI₅₀	0.27 μM Compound: Doxorubicin	Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 21875046]
A549	IC₅₀	0.29 μM Compound: DOX	Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method	[PMID: 25061803]
A549	IC₅₀	0.29 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by XTT assay Cytotoxicity against human A549 cells after 72 hrs by XTT assay	[PMID: 19647439]
A549	IC₅₀	0.32 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 25737400]
A549	IC₅₀	0.33 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 20732814]
A549	IC₅₀	0.33 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 26496013]
A549	IC₅₀	0.34 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30389295]
A549	IC₅₀	0.34 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21174408]
A549	IC₅₀	0.35 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 19691312]
A549	IC₅₀	0.35 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33940466]
A549	IC₅₀	0.36 μM Compound: Doxorubicin	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 21641694]
A549	IC₅₀	0.36 μM Compound: Doxorubucin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 20718475]
A549	IC₅₀	0.36 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method	[PMID: 17622129]
A549	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26397393]
A549	IC₅₀	0.37 μM Compound: DOX	Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
A549	IC₅₀	0.38 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining	10.1007/s00044-012-0025-y
A549	IC₅₀	0.39 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay	10.1007/s00044-011-9903-y
A549	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 16724859]
A549	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by Alamar Blue assay Cytotoxicity against human A549 cells by Alamar Blue assay	[PMID: 27536968]
A549	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30869892]
A549	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 18547115]
A549	IC₅₀	0.4 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 4 days by MTT assay Cytotoxicity against human A549 cells after 4 days by MTT assay	[PMID: 19824618]
A549	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28927795]
A549	IC₅₀	0.4 μM Compound: Doxo	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20334960]
A549	IC₅₀	0.41 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23548547]
A549	IC₅₀	0.411 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 24231309]
A549	IC₅₀	0.414 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 25497963]
A549	IC₅₀	0.42 μg/mL Compound: doxo	Cytotoxicity against human A549 cells by MTT method Cytotoxicity against human A549 cells by MTT method	[PMID: 17417907]
A549	IC₅₀	0.42 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 35818137]
A549	IC₅₀	0.43 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
A549	IC₅₀	0.44 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	10.1007/s00044-013-0777-z
A549	IC₅₀	0.44 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25078311]
A549	IC₅₀	0.44 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24836071]
A549	IC₅₀	0.45 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 26947606]
A549	IC₅₀	0.459 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 2 days by MTT assay Cytotoxicity against human A549 cells after 2 days by MTT assay	[PMID: 23932340]
A549	IC₅₀	0.459 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 24287557]
A549	IC₅₀	0.46 μM Compound: Doxorubicin	In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay	[PMID: 24742385]
A549	IC₅₀	0.47 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31704206]
A549	IC₅₀	0.477 μM Compound: Dox	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21983438]
A549	IC₅₀	0.477 μM Compound: Doxorubicin	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	[PMID: 21570750]
A549	IC₅₀	0.477 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	10.1039/C0MD00219D
A549	IC₅₀	0.48 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 31671309]
A549	IC₅₀	0.48 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 30576904]
A549	IC₅₀	0.48 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 30253344]
A549	IC₅₀	0.48 μM Compound: DOX	Antiproliferative activity against human A549 cells after 24 hrs by SRB assay Antiproliferative activity against human A549 cells after 24 hrs by SRB assay	[PMID: 30106296]
A549	IC₅₀	0.5 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35526504]
A549	IC₅₀	0.5 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 31148449]
A549	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27015002]
A549	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay	[PMID: 23664877]
A549	IC₅₀	0.51 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21708464]
A549	IC₅₀	0.51 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26356746]
A549	IC₅₀	0.52 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 18590313]
A549	IC₅₀	0.52 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 21071221]
A549	IC₅₀	0.53 μM Compound: Doxorubicin	Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
A549	IC₅₀	0.54 μg/mL Compound: Doxorubicin	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	[PMID: 31404864]
A549	IC₅₀	0.54 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23434227]
A549	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay	[PMID: 28159416]
A549	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by Alamar blue assay Cytotoxicity against human A549 cells by Alamar blue assay	[PMID: 27256910]
A549	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 30654238]
A549	IC₅₀	0.55 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
A549	IC₅₀	0.56 μM Compound: ADM	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A549	IC₅₀	0.58 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 31820976]
A549	IC₅₀	0.59 μM Compound: Doxo	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 21800859]
A549	IC₅₀	0.59 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 33276990]
A549	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36693198]
A549	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29702447]
A549	GI₅₀	0.6 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
A549	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 29975532]
A549	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25172418]
A549	IC₅₀	0.63 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21106454]
A549	IC₅₀	0.63 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 29614418]
A549	IC₅₀	0.63 μM Compound: Dox	Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30031974]
A549	IC₅₀	0.63 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
A549	GI₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 21885166]
A549	IC₅₀	0.665 μg/mL Compound: E; DOX	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35963130]
A549	IC₅₀	0.69 μM Compound: adriamycin	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26295905]
A549	IC₅₀	0.69 μM Compound: ADM	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 25089733]
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 32324401]
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay	10.1007/s00044-012-0402-6
A549	IC₅₀	0.7 μM Compound: Dox	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 28865276]
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay	10.1007/s00044-012-0370-x
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 24300737]
A549	IC₅₀	0.7 μM Compound: Doxorubicine	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22014995]
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
A549	IC₅₀	0.72 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19406535]
A549	IC₅₀	0.72 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22070654]
A549	IC₅₀	0.73 μM Compound: Doxo	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C2MD20302B
A549	IC₅₀	0.73 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
A549	IC₅₀	0.74 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
A549	IC₅₀	0.74 μM Compound: doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23806110]
A549	IC₅₀	0.75 μM Compound: adriamycin	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 17583953]
A549	IC₅₀	0.76 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
A549	IC₅₀	0.766 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30599418]
A549	IC₅₀	0.79 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 16252914]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 26252628]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24780595]
A549	IC₅₀	0.8 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24507927]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30679134]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26551342]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21035234]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 26774921]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 26646219]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25241926]
A549	IC₅₀	0.8 μM Compound: ADM	Cytotoxicity against human A549 cells by SRB method Cytotoxicity against human A549 cells by SRB method	[PMID: 29144133]
A549	IC₅₀	0.8 μM Compound: ADM	Cytotoxic activity against human A549 cells by SRB method Cytotoxic activity against human A549 cells by SRB method	[PMID: 25611519]
A549	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 31404864]
A549	IC₅₀	0.837 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19860383]
A549	IC₅₀	0.84 μM Compound: Doxorubicin	Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay	10.1007/s00044-013-0497-4
A549	IC₅₀	0.84 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19689125]
A549	IC₅₀	0.86 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 18419154]
A549	IC₅₀	0.86 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by WST-8 assay Cytotoxicity against human A549 cells by WST-8 assay	[PMID: 29295796]
A549	IC₅₀	0.87 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25419616]
A549	IC₅₀	0.89 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
A549	IC₅₀	0.89 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28554092]
A549	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	10.1039/C3MD00166K
A549	IC₅₀	0.9 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 34323485]
A549	EC₅₀	0.9 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 72 hrs Cytotoxicity against human A549 cells after 72 hrs	[PMID: 17378530]
A549	IC₅₀	0.91 μM Compound: Dox	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 35339100]
A549	IC₅₀	0.95 μM Compound: DOXO	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
A549	IC₅₀	0.95 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
A549	IC₅₀	0.95 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay	[PMID: 31784322]
A549	IC₅₀	0.95 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27016707]
A549	IC₅₀	0.96 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32438251]
A549	GI₅₀	0.97 μM Compound: Dox	Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
A549	IC₅₀	0.97 μM Compound: Doxorubicin	Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32531682]
A549	IC₅₀	0.97 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 17827007]
A549	IC₅₀	0.97 μM Compound: Doxorubicin	Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay. Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.	[PMID: 14643344]
A549	IC₅₀	0.98 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25747499]
A549	IC₅₀	1 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22044164]
A549	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 32915576]
A549	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23079527]
A549	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21996519]
A549	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]
A549	ED₅₀	1.01 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8676130]
A549	ED₅₀	1.01 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7673926]
A549	IC₅₀	1.01 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
A549	IC₅₀	1.02 μM Compound: Dox	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22209733]
A549	IC₅₀	1.05 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
A549	IC₅₀	1.06 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
A549	IC₅₀	1.06 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26708114]
A549	IC₅₀	1.07 μM Compound: DOX	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 31057738]
A549	ED₅₀	1.1 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7714532]
A549	ED₅₀	1.1 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 8021648]
A549	IC₅₀	1.1 μM Compound: Doxorubicin	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	10.1039/C4MD00219A
A549	GI₅₀	1.1 μM Compound: Dox	Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
A549	IC₅₀	1.11 μM Compound: DOX	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 25933593]
A549	ED₅₀	1.13 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 11325235]
A549	IC₅₀	1.15 μM Compound: ADM	Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35803175]
A549	IC₅₀	1.18 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22472043]
A549	IC₅₀	1.2 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17918910]
A549	IC₅₀	1.2 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay	[PMID: 32682198]
A549	IC₅₀	1.2 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB protein staining method Cytotoxicity against human A549 cells by SRB protein staining method	[PMID: 25781655]
A549	GI₅₀	1.21 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 31128433]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 31108261]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25172420]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 24113366]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23911578]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23764302]
A549	IC₅₀	1.28 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25703298]
A549	ED₅₀	1.3 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 10395501]
A549	IC₅₀	1.3 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by WST assay Cytotoxicity against human A549 cells after 24 hrs by WST assay	[PMID: 25881821]
A549	IC₅₀	1.303 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29501940]
A549	IC₅₀	1.32 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
A549	IC₅₀	1.4 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22413887]
A549	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 29035560]
A549	IC₅₀	1.43 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	1.445 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28462842]
A549	ED₅₀	1.48 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 8201311]
A549	ED₅₀	1.48 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 1593281]
A549	IC₅₀	1.495 μM Compound: Doxorubicin	Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A549	IC₅₀	1.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
A549	IC₅₀	1.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25453799]
A549	IC₅₀	1.58 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26330077]
A549	IC₅₀	1.58 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26264845]
A549	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
A549	IC₅₀	1.65 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 24418772]
A549	IC₅₀	1.68 μM Compound: II	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 29289881]
A549	ED₅₀	1.7 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 9917277]
A549	IC₅₀	1.7 μM Compound: Doxorubicin	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 28916158]
A549	IC₅₀	1.778 μM Compound: Doxorubicin	Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 27744185]
A549	ED₅₀	1.78 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8946743]
A549	IC₅₀	1.78 μM Compound: Doxorubicin	Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 25966052]
A549	IC₅₀	1.79 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35339645]
A549	IC₅₀	1.86 μM Compound: Doxo	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29129513]
A549	IC₅₀	1.88 μM Compound: Dox	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	10.1007/s00044-013-0584-6
A549	IC₅₀	1.9 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
A549	IC₅₀	1.9 μM Compound: Doxorubicin	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25615796]
A549	IC₅₀	1.9 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 19632833]
A549	IC₅₀	1.9 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
A549	IC₅₀	1.9 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19394829]
A549	GI₅₀	1.9 μM Compound: Doxorubicin	Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
A549	ED₅₀	1.91 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9599260]
A549	IC₅₀	1.945 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
A549	IC₅₀	1.986 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 26301558]
A549	IC₅₀	1.99 μM Compound: Doxorubicin	Cytotoxicity against human lung carcinoma A549 cell line using MTT assay Cytotoxicity against human lung carcinoma A549 cell line using MTT assay	[PMID: 9873387]
A549	IC₅₀	10.2 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28886509]
A549	IC₅₀	10.28 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35635947]
A549	CC₅₀	10.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 29792325]
A549	IC₅₀	10.55 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	10.1039/C3MD00013C
A549	IC₅₀	10.76 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 33183865]
A549	IC₅₀	10.83 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 36463726]
A549	IC₅₀	11 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28919340]
A549	IC₅₀	11.62 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay	[PMID: 28129977]
A549	GI₅₀	13.01 μM Compound: ADR	Anticancer activity against human A549 cells by SRB method Anticancer activity against human A549 cells by SRB method	[PMID: 22104151]
A549	IC₅₀	13.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 24681979]
A549	IC₅₀	14 μM Compound: Doxo	Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay	[PMID: 25468043]
A549	IC₅₀	14.7 nM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay	[PMID: 31655432]
A549	IC₅₀	140 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 35213166]
A549	IC₅₀	149 nM Compound: DX	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	[PMID: 34592435]
A549	IC₅₀	15.07 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	10.1039/C2MD20023F
A549	IC₅₀	15.07 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 22386528]
A549	ED₅₀	152 μM Compound: doxorubicin	Antitumor activity against human A549 cells after 24 hrs by MTT assay Antitumor activity against human A549 cells after 24 hrs by MTT assay	[PMID: 17482824]
A549	IC₅₀	17 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34838335]
A549	IC₅₀	172 nM Compound: DX	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33611191]
A549	IC₅₀	18.56 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28262524]
A549	IC₅₀	190 nM Compound: DX	Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay	[PMID: 34116158]
A549	ED₅₀	2 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8882437]
A549	IC₅₀	2.04 μM Compound: DOX	Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
A549	IC₅₀	2.1 μM Compound: Doxo (I)	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	10.1039/C4MD00228H
A549	IC₅₀	2.1 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay	[PMID: 34838335]
A549	IC₅₀	2.1 μM Compound: Dox	Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
A549	IC₅₀	2.12 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 26874744]
A549	IC₅₀	2.12 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25462233]
A549	IC₅₀	2.17 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
A549	IC₅₀	2.18 μM Compound: Doxorubicin	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22136907]
A549	IC₅₀	2.2 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 9644064]
A549	IC₅₀	2.2 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21425785]
A549	IC₅₀	2.2 μM Compound: adriamycin	Cytotoxicity against human A549 cells by rapid colorimetric assay Cytotoxicity against human A549 cells by rapid colorimetric assay	[PMID: 19585998]
A549	IC₅₀	2.23 μM Compound: DOX	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 20171108]
A549	IC₅₀	2.3 μM Compound: DOX	Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 30846253]
A549	IC₅₀	2.3 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
A549	IC₅₀	2.31 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33352388]
A549	IC₅₀	2.34 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26948541]
A549	ED₅₀	2.43 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8904848]
A549	IC₅₀	2.48 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
A549	IC₅₀	2.58 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
A549	IC₅₀	2.6 x 10^-1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by XTT assay Cytotoxicity against human A549 cells after 72 hrs by XTT assay	[PMID: 20619940]
A549	IC₅₀	2.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 25300819]
A549	IC₅₀	2.67 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs	[PMID: 32736079]
A549	IC₅₀	2.7 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT colorimetric method Cytotoxicity against human A549 cells by MTT colorimetric method	[PMID: 23043498]
A549	IC₅₀	2.8 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22647719]
A549	IC₅₀	2.8 μM Compound: Adriamycin	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 21721519]
A549	IC₅₀	2.81 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27015609]
A549	IC₅₀	2.905 μM Compound: DOX	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 29509413]
A549	ED₅₀	2.94 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9584396]
A549	ED₅₀	2.94 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7673936]
A549	IC₅₀	22 nM Compound: doxorubicin	Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.	[PMID: 10956214]
A549	IC₅₀	228.2 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29886322]
A549	IC₅₀	24.27 μM Compound: DOX	Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0018-x
A549	IC₅₀	258 nM Compound: DOX; DX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay	[PMID: 31653441]
A549	IC₅₀	258 nM Compound: Doxorubicin	Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
A549	IC₅₀	26.81 μM Compound: DOX	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 25912674]
A549	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay	[PMID: 33461146]
A549	IC₅₀	3.03 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25594739]
A549	IC₅₀	3.08 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
A549	ED₅₀	3.1 x 10^-4 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 7714533]
A549	IC₅₀	3.118 μg/mL Compound: ADM	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25862199]
A549	IC₅₀	3.13 μM Compound: Dox	Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay	[PMID: 24161704]
A549	IC₅₀	3.13 μM Compound: Doxo	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25563891]
A549	IC₅₀	3.14 μM Compound: DOX	Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 27149641]
A549	IC₅₀	3.16 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30500683]
A549	IC₅₀	3.19 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 33148490]
A549	IC₅₀	3.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	10.1039/C4MD00566J
A549	IC₅₀	3.24 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay	[PMID: 32631524]
A549	IC₅₀	3.28 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 22542958]
A549	IC₅₀	3.3 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 27055942]
A549	IC₅₀	3.3 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31546197]
A549	IC₅₀	3.35 μM Compound: DOX	Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay	[PMID: 30746067]
A549	IC₅₀	3.4 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25453802]
A549	IC₅₀	3.4 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30398868]
A549	ED₅₀	3.41 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7494147]
A549	IC₅₀	3.41 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by CCK8 assay Cytotoxicity against human A549 cells by CCK8 assay	[PMID: 29452840]
A549	ED₅₀	3.56 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7673935]
A549	ED₅₀	3.56 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7494150]
A549	IC₅₀	3.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 94 hrs by MTT assay Cytotoxicity against human A549 cells after 94 hrs by MTT assay	[PMID: 21868138]
A549	ED₅₀	3.67 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9599253]
A549	IC₅₀	3.69 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 22472043]
A549	ED₅₀	3.93 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9322367]
A549	IC₅₀	3.97 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31404864]
A549	IC₅₀	3.98 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	10.1007/s00044-013-0784-0
A549	IC₅₀	4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23792352]
A549	IC₅₀	4 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23748152]
A549	IC₅₀	4.11 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 24095746]
A549	IC₅₀	4.36 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 30503942]
A549	ED₅₀	4.47 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	10.1021/np970510f
A549	IC₅₀	4.91 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
A549	IC₅₀	4.91 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
A549	IC₅₀	4.91 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
A549	IC₅₀	4.91 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28135634]
A549	IC₅₀	4.91 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
A549	IC₅₀	4.91 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
A549	ED₅₀	4.99 ng/mL Compound: adr	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9461654]
A549	ED₅₀	4.99 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9014350]
A549	IC₅₀	426 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay	[PMID: 29190084]
A549	IC₅₀	459 nM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30878835]
A549	IC₅₀	5 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 29072457]
A549	ED₅₀	5.04 x 10^-4 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 1453182]
A549	ED₅₀	5.06 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8882434]
A549	IC₅₀	5.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 27894044]
A549	IC₅₀	5.13 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35367708]
A549	ED₅₀	5.3 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9214729]
A549	IC₅₀	5.3 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 31589431]
A549	IC₅₀	5.32 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 27476117]
A549	IC₅₀	5.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay	[PMID: 34223162]
A549	IC₅₀	5.58 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
A549	IC₅₀	5.93 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 32311607]
A549	ED₅₀	59.5 nM Compound: doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17655260]
A549	IC₅₀	6.13 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability by SRB assay Cytotoxicity against human A549 cells assessed as cell viability by SRB assay	[PMID: 26022842]
A549	ED₅₀	6.22 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 15730242]
A549	IC₅₀	6.22 μM Compound: Doxo	Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay	[PMID: 31104996]
A549	IC₅₀	6.61 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 22182926]
A549	IC₅₀	69.33 μM Compound: Doxorubicin	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	[PMID: 25743216]
A549	IC₅₀	7.1 μM Compound: DX	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	10.1039/C5MD00513B
A549	GI₅₀	7.25 μM Compound: adriamycin	Cytotoxicity against human A549 cells after 24 hrs by SRB method Cytotoxicity against human A549 cells after 24 hrs by SRB method	[PMID: 18262426]
A549	GI₅₀	7.25 μM Compound: ADR	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 20031423]
A549	GI₅₀	7.25 μM Compound: ADR	Growth inhibition of human A549 cells by SRB assay Growth inhibition of human A549 cells by SRB assay	[PMID: 22361684]
A549	GI₅₀	7.25 μM Compound: ADR	Anticancer activity against human A549 cells by SRB method Anticancer activity against human A549 cells by SRB method	[PMID: 21676506]
A549	GI₅₀	7.25 μM Compound: ADR, Adriamycin	Growth inhibition of human A549 cells by SRB method Growth inhibition of human A549 cells by SRB method	[PMID: 18207392]
A549	GI₅₀	7.25 μM Compound: ADR	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
A549	GI₅₀	7.25 μM Compound: ADR	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
A549	GI₅₀	7.25 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
A549	GI₅₀	7.25 μM Compound: ADR	Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
A549	IC₅₀	7.47 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24607876]
A549	IC₅₀	7.52 μM Compound: Dox	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 26494582]
A549	IC₅₀	7.86 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30108986]
A549	IC₅₀	7.88 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18440233]
A549	IC₅₀	740 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30172625]
A549	IC₅₀	8.05 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25140752]
A549	GI₅₀	8.14 μM Compound: Doxo	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26513642]
A549	IC₅₀	8.5 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay	[PMID: 26048808]
A549	IC₅₀	8.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 33766771]
A549	IC₅₀	8.73 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36439979]
A549	ED₅₀	9.2 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 hrs by MTT assay Cytotoxicity against human A549 cells after 7 hrs by MTT assay	[PMID: 7623031]
A549	IC₅₀	9.2 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20846862]
A549	IC₅₀	9.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35526504]
A549	IC₅₀	9.7 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25655719]
A549	IC₅₀	90 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay	[PMID: 33016067]
A549/CDDP	IC₅₀	4.59 μM Compound: DOX	Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay	[PMID: 29509413]
A673	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
A673	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
A673	EC₅₀	0.39 μM Compound: Doxorubicin	Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay	[PMID: 23600925]
A704	IC₅₀	2 μM Compound: Doxorubicin	Cytotoxicity against human A704 cells after 72 hrs by MTT assay Cytotoxicity against human A704 cells after 72 hrs by MTT assay	[PMID: 19406535]
ACHN	IC₅₀	0.001 μM Compound: doxo	Antiproliferative activity against human ACHN cell line by MTT assay Antiproliferative activity against human ACHN cell line by MTT assay	[PMID: 16913700]
ACHN	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 34851111]
ACHN	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay	[PMID: 28617598]
ACHN	IC₅₀	0.04 μM Compound: Doxo	Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
ACHN	IC₅₀	0.04 μM Compound: Doxorubicin	Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay	[PMID: 19053767]
ACHN	GI₅₀	0.08 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human ACHN cells after 48 hrs by SRB assay Cytotoxicity against human ACHN cells after 48 hrs by SRB assay	[PMID: 23871905]
ACHN	GI₅₀	0.08 μM Compound: ADR	Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30253887]
ACHN	GI₅₀	0.08 μM Compound: ADR	Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 28870801]
ACHN	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
ACHN	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
ACHN	GI₅₀	0.088 μM Compound: ADR	Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method	[PMID: 34500188]
ACHN	GI₅₀	0.0995 μM Compound: ADR	Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay	[PMID: 27096046]
ACHN	GI₅₀	0.2 μM Compound: ADR	Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 25953156]
ACHN	GI₅₀	0.22 μM Compound: Doxorubicin	Anticancer activity against human ACHN cells by SRB assay Anticancer activity against human ACHN cells by SRB assay	[PMID: 20732810]
ACHN	GI₅₀	0.41 μM Compound: Doxorubicin	Cytotoxicity against human ACHN cells by SRB assay Cytotoxicity against human ACHN cells by SRB assay	[PMID: 19596579]
ACHN	IC₅₀	0.79 μM Compound: Doxorubicin	Anticancer activity against human ACHN cells after 48 hrs by MTT assay Anticancer activity against human ACHN cells after 48 hrs by MTT assay	[PMID: 22136907]
ACHN	GI₅₀	1.63 μM Compound: ADR	Antiproliferative activity against human ACHN cells by SRB method Antiproliferative activity against human ACHN cells by SRB method	[PMID: 24835787]
ACHN	GI₅₀	1.63 μM Compound: ADR	Antiproliferative activity against human ACHN cells by SRB assay Antiproliferative activity against human ACHN cells by SRB assay	[PMID: 22738641]
ACHN	IC₅₀	14.2 μM Compound: doxorubicin	Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay	[PMID: 16562840]
ACHN	GI₅₀	2 μM Compound: Doxorubicin	Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay	[PMID: 23964644]
ACHN	IC₅₀	2.08 μg/mL Compound: Doxorubicin	Cytotoxicity against human ACHN cells by MTT assay Cytotoxicity against human ACHN cells by MTT assay	10.1039/C4MD00566J
ADR5000 cell line	IC₅₀	> 10 μM Compound: Doxo	Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
ADR5000 cell line	IC₅₀	> 10 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells after 48 hrs by MTT assay Cytotoxicity against human CEM/ADR5000 cells after 48 hrs by MTT assay	[PMID: 32496057]
ADR5000 cell line	IC₅₀	> 5.2 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 by CCK-8 assay Cytotoxicity against human CEM/ADR5000 by CCK-8 assay	[PMID: 22884578]
ADR5000 cell line	IC₅₀	> 5.2 μM Compound: doxorubicin	Cytotoxicity against human CEM/ADR5000 by XTT assay Cytotoxicity against human CEM/ADR5000 by XTT assay	[PMID: 20527917]
ADR5000 cell line	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human CEM/ADR5000 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human CEM/ADR5000 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
ADR5000 cell line	IC₅₀	1.61 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay	[PMID: 26260339]
ADR5000 cell line	IC₅₀	1.61 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay	[PMID: 28456567]
ADR5000 cell line	IC₅₀	122.96 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
ADR5000 cell line	IC₅₀	23.27 μM Compound: Doxorubicin	Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay	[PMID: 24561670]
ADR5000 cell line	EC₅₀	23.27 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29937978]
ADR5000 cell line	IC₅₀	30.07 μM Compound: Doxorubicin	Growth inhibition of human multi-drug resistant CEM/ADR5000 cells by resazurin assay Growth inhibition of human multi-drug resistant CEM/ADR5000 cells by resazurin assay	[PMID: 28121440]
ADR5000 cell line	IC₅₀	30.07 μM Compound: Doxorubicin	Antileukemic activity against human CEM/ADR5000 cells after 24 to 48 hrs by resazurin dye based fluorescence assay Antileukemic activity against human CEM/ADR5000 cells after 24 to 48 hrs by resazurin dye based fluorescence assay	[PMID: 29560715]
ADR5000 cell line	IC₅₀	30.07 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay	[PMID: 32663024]
ADR5000 cell line	EC₅₀	41.54 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29887512]
AGS	GI₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 21875046]
AGS	GI₅₀	0.02 μM Compound: Doxorubicin	Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay	10.1007/s00044-012-0232-6
AGS	IC₅₀	0.31 μM Compound: adriamycin	Cytotoxicity against human AGS cells by MTT assay Cytotoxicity against human AGS cells by MTT assay	[PMID: 17125240]
AGS	IC₅₀	1.2 μM Compound: doxorubicin	Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23806110]
AGS	IC₅₀	10.9 μM Compound: ADR	Cytotoxicity against human AGS cells after 48 hrs by MTT assay Cytotoxicity against human AGS cells after 48 hrs by MTT assay	10.1039/C2MD20270K
ARPE-19	IC₅₀	0.76 μM Compound: Doxorubicin	Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
ASPC1	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay	[PMID: 36734533]
ASPC1	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human ASPC1 cells by SRB assay Cytotoxicity against human ASPC1 cells by SRB assay	[PMID: 33371684]
ASPC1	IC₅₀	0.86 μM Compound: Doxorubicin	Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay	[PMID: 31158748]
ASPC1	IC₅₀	1.87 μM Compound: Adriamycin	Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay	[PMID: 24717154]
AT3B-1	IC₅₀	167.5 μM Compound: 1, Dox	Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay	[PMID: 16168650]
B16	IC₅₀	< 0.001 μg/mL Compound: 1 (doxorubicin)	In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration	[PMID: 15013011]
B16	IC₅₀	< 0.1 μM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 22330634]
B16	IC₅₀	0.001 μg/mL Compound: 1 (doxorubicin)	In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration	[PMID: 15013011]
B16	IC₅₀	0.03 μg/mL Compound: Doxorubicin	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 18586355]
B16	IC₅₀	0.03 μg/mL Compound: doxorubicin	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 17827021]
B16	IC₅₀	0.03 μg/mL Compound: doxorubicin	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 15787450]
B16	IC₅₀	0.03 μM Compound: Doxorubicin	Anticancer activity against mouse B16 cells after 48 hrs by MTT assay Anticancer activity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 22668451]
B16	IC₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against murine B16 cells by MTT assay Cytotoxicity against murine B16 cells by MTT assay	[PMID: 17256903]
B16	IC₅₀	0.14 μM Compound: DOX	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 21496972]
B16	IC₅₀	0.18 μM Compound: ADM	Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
B16	IC₅₀	0.18 μM Compound: ADM	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 25529742]
B16	IC₅₀	0.18 μM Compound: Doxorubicin	Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay	[PMID: 25247772]
B16	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 30659997]
B16	IC₅₀	0.43 μM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26934105]
B16	IC₅₀	1.7 μM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 22304344]
B16	IC₅₀	17.67 μM Compound: doxorubicin	Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 26200396]
B16	IC₅₀	2.78 μM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25594739]
B16	IC₅₀	21.5 μM Compound: Doxorubicin	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 21620529]
B16	IC₅₀	3.16 μg/mL Compound: Doxorubicin	Cytotoxicity against mouse B16 cells by MTT assay Cytotoxicity against mouse B16 cells by MTT assay	10.1039/C4MD00566J
B16	IC₅₀	670 nM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 30172625]
B16	IC₅₀	7.6 nM Compound: Adriamycin	Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay	[PMID: 10377224]
B16-BL6	IC₅₀	3.07 μM Compound: Doxorubicin	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 19689125]
B16-BL6	IC₅₀	8.05 μM Compound: Doxorubicin	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 18440233]
B16-F1	IC₅₀	0.23 μM Compound: Doxorubicin	Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
B16-F10	IC₅₀	0.016 μM Compound: DOX	Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
B16-F10	IC₅₀	0.072 μM Compound: Doxorubicin	Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay	[PMID: 23777898]
B16-F10	IC₅₀	0.12 μM Compound: Adriamycin	Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay	[PMID: 24717154]
B16-F10	IC₅₀	0.19 μM Compound: ADM	Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 30344912]
B16-F10	IC₅₀	0.346 μM Compound: Doxorubicin	Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
B16-F10	IC₅₀	0.663 μM Compound: Dox	Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
B16-F10	IC₅₀	2.3 μM Compound: Doxorubicin	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27300257]
B16-F10	IC₅₀	3.28 μM Compound: Doxorubicin	Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34124677]
B16-F10	IC₅₀	4.23 μM Compound: Doxorubicin	Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
B16-F10	IC₅₀	4.33 μM Compound: Doxorubicin	Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay	[PMID: 30433783]
B16-F10-luc2	IC₅₀	0.04 μM Compound: 1	Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay	[PMID: 34411983]
B16-F10-luc2	IC₅₀	0.04 μM Compound: 1	Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay	[PMID: 34411983]
B16-F10-luc2	IC₅₀	0.09 μM Compound: 1	Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay	[PMID: 34411983]
B16-F10-luc2	IC₅₀	0.11 μM Compound: 1	Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay	[PMID: 34411983]
BALB/3T3	IC₅₀	0.092 μM Compound: Doxorubicin	Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 32432867]
BALB/3T3	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay	[PMID: 26639764]
BALB/3T3	IC₅₀	0.18 μM Compound: doxorubicin	Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
BALB/3T3	IC₅₀	0.31 μM Compound: Doxorubicin	Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs	[PMID: 26163197]
BALB/3T3	GI₅₀	0.6 μM Compound: Dox	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	0.62 μM Compound: Dox	Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
BALB/3T3	IC₅₀	1.08 μM Compound: Doxorubicin	Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay	[PMID: 26496013]
BALB/3T3	IC₅₀	1.91 μM Compound: Doxorubicin	Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay	[PMID: 23079523]
BALB/3T3	IC₅₀	166 nM Compound: DOX; DX	Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay	[PMID: 31653441]
BALB/3T3	IC₅₀	166 nM Compound: Doxorubicin	Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
BALB/3T3	IC₅₀	200 nM Compound: DX	Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay	[PMID: 34116158]
BALB/3T3	IC₅₀	315 nM Compound: DX	Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34592435]
BALB/3T3	IC₅₀	32.3 nM Compound: DX	Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33611191]
BC	IC₅₀	0.17 μg/mL Compound: Doxorubicin	Cytotoxicity against human BC cells by colorimetric method Cytotoxicity against human BC cells by colorimetric method	[PMID: 16989536]
BC	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human BC cells by SRB assay Cytotoxicity against human BC cells by SRB assay	[PMID: 20038128]
BC	IC₅₀	2.88 x 10^-4 mM Compound: doxorubicin	Cytotoxicity against human BC cells by SRB assay Cytotoxicity against human BC cells by SRB assay	[PMID: 16933890]
Bcap37	IC₅₀	1.12 μM Compound: AMD	Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay	[PMID: 26900656]
Bcap37	IC₅₀	1.19 μM Compound: AMD	Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay	[PMID: 26807545]
Bcap37	IC₅₀	1.2 μM Compound: ADM	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 26280921]
Bcap37	IC₅₀	1.2 μM Compound: ADM	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 25874331]
Bcap37	IC₅₀	1.28 μM Compound: ADM	Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 23124210]
Bcap37	IC₅₀	1.9 μM Compound: ADM	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	10.1007/s00044-013-0854-3
Bcap37	IC₅₀	2 μM Compound: ADM	Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay	10.1039/C1MD00038A
Bcap37	IC₅₀	2.87 μM Compound: ADM	Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay	[PMID: 25965778]
BEAS-2B	GI₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay	[PMID: 30071406]
BEAS-2B	GI₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
BEAS-2B	IC₅₀	18.6 μM Compound: Doxorubicin	Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay	[PMID: 29471119]
BEAS-2B	IC₅₀	2.4 μM Compound: Doxorubicin	Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay	[PMID: 29471119]
Bel-7402	GI₅₀	< 1 μM Compound: DOX	Antiproliferative activity against human Bel7402 cells by MTT assay Antiproliferative activity against human Bel7402 cells by MTT assay	[PMID: 31990554]
Bel-7402	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human Bel-7402 cells by SRB assay Cytotoxicity against human Bel-7402 cells by SRB assay	[PMID: 33847126]
Bel-7402	IC₅₀	> 1 μM Compound: Doxorubicin	Antiproliferative activity against human Bel-7402 cells by MTT assay Antiproliferative activity against human Bel-7402 cells by MTT assay	[PMID: 36089748]
Bel-7402	IC₅₀	0.01 μg/mL Compound: ADR	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 18590312]
Bel-7402	IC₅₀	0.01 μg/mL Compound: ADR	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 18590312]
Bel-7402	IC₅₀	0.021 μM Compound: adriamycin	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 19028425]
Bel-7402	IC₅₀	0.049 μM Compound: Doxorubicin	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 20846862]
Bel-7402	IC₅₀	0.067 μM Compound: ADR	Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay	[PMID: 20949916]
Bel-7402	IC₅₀	0.12 μM Compound: Adriamycin	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 20593838]
Bel-7402	IC₅₀	0.22 μM Compound: ADM	Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
Bel-7402	IC₅₀	0.22 μM Compound: ADM	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 25529742]
Bel-7402	IC₅₀	0.22 μM Compound: Doxorubicin	Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay	[PMID: 25247772]
Bel-7402	IC₅₀	0.53 μM Compound: Adriamycin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 22070654]
Bel-7402	IC₅₀	0.58 μM Compound: Doxorubicin	Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay	[PMID: 20149494]
Bel-7402	IC₅₀	0.6 μM Compound: ADM	Cytotoxic activity against human Bel7402 cells by MTT method Cytotoxic activity against human Bel7402 cells by MTT method	[PMID: 25611519]
Bel-7402	IC₅₀	0.9 μM Compound: ADM	Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 20932754]
Bel-7402	IC₅₀	1 μM Compound: adriamycin	Cytotoxicity against human Bel-7402 cells by MTT assay Cytotoxicity against human Bel-7402 cells by MTT assay	[PMID: 17190442]
Bel-7402	IC₅₀	1.36 μM Compound: DOX	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 26386603]
Bel-7402	IC₅₀	5 μM Compound: Doxorubicin	Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay	[PMID: 20884091]
Bel-7402	IC₅₀	578.2 nM Compound: Doxorubicin	Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 24211639]
BEL-7404 tumor cell line	IC₅₀	0.13 μM Compound: DOX	Cytotoxicity against human Bel7404 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27668963]
BeWo	IC₅₀	1.07 μM Compound: Doxorubicin	Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
BeWo	IC₅₀	6.24 μg/mL Compound: (20) adriamycin	In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay	[PMID: 12620075]
BGC-823	IC₅₀	0.35 μM Compound: adriamycin	Cytotoxicity against human BGC823 cells after 48 hrs Cytotoxicity against human BGC823 cells after 48 hrs	[PMID: 17583953]
BGC-823	IC₅₀	0.405 μM Compound: ADR	Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay	[PMID: 30241010]
BGC-823	IC₅₀	0.66 μM Compound: DOX	Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
BGC-823	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 22749279]
BGC-823	IC₅₀	1 μM Compound: adriamycin	Cytotoxicity against human BGC-823 cells by MTT assay Cytotoxicity against human BGC-823 cells by MTT assay	[PMID: 17190442]
BGC-823	IC₅₀	1.33 μM Compound: Adriamycin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 23434227]
BGC-823	IC₅₀	1.48 μM Compound: Adriamycin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 24182355]
BGC-823	IC₅₀	2.6 μM Compound: ADM	Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay	10.1039/C1MD00038A
BGC-823	IC₅₀	4.8 μM Compound: Doxorubicin	Antitumor activity against human BGC823 cells after 48 hrs by SRB assay Antitumor activity against human BGC823 cells after 48 hrs by SRB assay	[PMID: 20884091]
BJ	IC₅₀	2.33 μM Compound: DOXO	Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
BJ	IC₅₀	2.33 μM Compound: Doxorubicin	Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
BJ	IC₅₀	2.7 μM Compound: Doxorubicin	Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay	[PMID: 19473028]
BMDM	IC₅₀	4.6 μM Compound: Adriamycin	Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay	[PMID: 22616554]
BT-474	IC₅₀	0.041 μM Compound: DOX	Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay	[PMID: 27769032]
BT-474	IC₅₀	0.053 μM Compound: DOX	Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay	[PMID: 27769032]
BT-474	IC₅₀	0.07 μM Compound: Dox	Cytotoxicity against human BT474 cells after 3 days by MTT assay Cytotoxicity against human BT474 cells after 3 days by MTT assay	[PMID: 21741833]
BT-474	IC₅₀	0.18 μM Compound: DOX	Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay	[PMID: 27769032]
BT-474	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay	[PMID: 28494255]
BT-474	IC₅₀	1.9 μM Compound: DOX	Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
BT-474	IC₅₀	8.92 μg/mL Compound: doxorubicin	Cytotoxicity against human BT474 cells after 3 days by MTT assay Cytotoxicity against human BT474 cells after 3 days by MTT assay	[PMID: 19456120]
BT-549	IC₅₀	< 0.55 μg/mL Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay	[PMID: 19105653]
BT-549	IC₅₀	< 0.55 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining	10.1007/s00044-011-9587-3
BT-549	IC₅₀	< 1.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay	[PMID: 11374943]
BT-549	IC₅₀	0.008 μg/mL Compound: doxorubicin	Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay	[PMID: 8984156]
BT-549	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
BT-549	GI₅₀	0.01 μM Compound: Doxorubicin	Cytostatic activity against human BT549 cells after 5 days by SRB assay Cytostatic activity against human BT549 cells after 5 days by SRB assay	[PMID: 21711054]
BT-549	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
BT-549	IC₅₀	0.045 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay	[PMID: 29317147]
BT-549	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
BT-549	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control	[PMID: 25975638]
BT-549	GI₅₀	0.23 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 23871905]
BT-549	GI₅₀	0.23 μM Compound: Doxorubicin	Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
BT-549	GI₅₀	0.23 μM Compound: Doxorubicin	Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
BT-549	IC₅₀	0.6 μg/mL Compound: doxorubicin	Cytotoxicity against human BT549 cells by neutral red assay Cytotoxicity against human BT549 cells by neutral red assay	[PMID: 17976995]
BT-549	IC₅₀	0.8 μg/mL Compound: doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye	[PMID: 20550123]
BT-549	IC₅₀	1 μg/mL Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining	[PMID: 15165136]
BT-549	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay	[PMID: 19658408]
BT-549	IC₅₀	1.3 μg/mL Compound: doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining	[PMID: 19928902]
BT-549	IC₅₀	1.35 μg/mL Compound: Doxorubicin	Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay	[PMID: 27769668]
BT-549	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay	[PMID: 26005918]
BT-549	IC₅₀	1.96 μM Compound: doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay	[PMID: 19879765]
BT-549	IC₅₀	2.6 μM Compound: doxorubicin	Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method	[PMID: 22530813]
BT-549	IC₅₀	3.6 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay	[PMID: 27618204]
BT-549	IC₅₀	3.7 μM Compound: doxorubicin	Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
BXPC-3	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
BXPC-3	IC₅₀	0.4 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 24095089]
BXPC-3	IC₅₀	0.56 μM Compound: Doxorubicin	Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay	[PMID: 28554092]
BXPC-3	IC₅₀	1.78 μM Compound: Doxorubicin	Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 26253231]
BXPC-3	IC₅₀	13 μM Compound: Doxorubicin	Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay	[PMID: 27173802]
BXPC-3	IC₅₀	13.56 μM Compound: Doxorubicin	Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay	[PMID: 29573910]
BXPC-3	IC₅₀	14.3 μM Compound: Doxorubicin	Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28254167]
BXPC-3	IC₅₀	9.12 μM Compound: Doxorubicin	Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay	[PMID: 30072225]
C2D cell line	IC₅₀	46.5 nM Compound: Doxorubicin	Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay	[PMID: 14971910]
C2G cell line	IC₅₀	28.7 nM Compound: Doxorubicin	Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay	[PMID: 14971910]
C-33-A	IC₅₀	0.28 μg/mL Compound: Doxorubicin	Cytotoxicity against human C33A cells after 48 hrs by SRB assay Cytotoxicity against human C33A cells after 48 hrs by SRB assay	[PMID: 20732814]
C-33-A	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay	[PMID: 21071221]
C3H	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay	[PMID: 26810263]
C6	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against rat C6 cells after 72 hrs by MTT assay Cytotoxicity against rat C6 cells after 72 hrs by MTT assay	[PMID: 30659997]
C6	IC₅₀	0.5 μM Compound: Dox	Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay	[PMID: 28504888]
C6	IC₅₀	25.64 μM Compound: Dox	Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 33183865]
C8166	IC₅₀	0.02 μM Compound: doxo	Antiproliferative activity against human C8166 cell line by MTT assay Antiproliferative activity against human C8166 cell line by MTT assay	[PMID: 16913700]
Ca9-22	IC₅₀	0.09 μg/mL Compound: Doxorubicin	Cytotoxicity against human sCa9-22 cells by MTT assay Cytotoxicity against human sCa9-22 cells by MTT assay	[PMID: 18590313]
Ca9-22	IC₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 18973388]
Ca9-22	IC₅₀	0.14 μg/mL Compound: Doxorubicin	Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay	[PMID: 19691312]
Ca9-22	IC₅₀	0.26 μM Compound: Doxo	Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay	[PMID: 21800859]
Ca9-22	IC₅₀	0.31 μg/mL Compound: doxorubicin	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 22413887]
Ca9-22	CC₅₀	0.7 μM Compound: DXR	Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31532650]
Ca9-22	IC₅₀	1.3 μM Compound: Doxo	Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay	[PMID: 20334960]
Ca9-22	IC₅₀	14.47 μg/mL Compound: Doxorubicin	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 21106454]
Caco-2	IC₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay	[PMID: 25534608]
Caco-2	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
Caco-2	IC₅₀	0.05 μM Compound: Doxorubicine	Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Caco-2	IC₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Caco-2	IC₅₀	0.17 μM Compound: Doxorubicin	Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
Caco-2	GI₅₀	0.32 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay	[PMID: 24184076]
Caco-2	IC₅₀	0.35 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
Caco-2	IC₅₀	0.6 μM Compound: Doxorubicin	Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
Caco-2	IC₅₀	0.73 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay	[PMID: 29885574]
Caco-2	IC₅₀	0.96 μM Compound: Doxorubicin	Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26874404]
Caco-2	IC₅₀	1 μg/mL Compound: Doxorubicin	Cytotoxicity against human Caco-2 cells after 24 hrs Cytotoxicity against human Caco-2 cells after 24 hrs	[PMID: 20207452]
Caco-2	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
Caco-2	IC₅₀	2.7 μM Compound: Adriamycin	Cytotoxicity against human Caco2 cells by MTT assay Cytotoxicity against human Caco2 cells by MTT assay	[PMID: 22946634]
Caco-2	IC₅₀	21 μM Compound: 21	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32435401]
Caco-2	IC₅₀	26.79 μM Compound: DOX	Antiproliferative activity against human Caco2 cells by MTT assay Antiproliferative activity against human Caco2 cells by MTT assay	[PMID: 30216848]
Caco-2	IC₅₀	3 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 26874744]
Caco-2	IC₅₀	3.83 μM Compound: Dox	Antiproliferative activity against human Caco2 cells by MTT assay Antiproliferative activity against human Caco2 cells by MTT assay	[PMID: 28802125]
Caco-2	IC₅₀	48.1 nM Compound: DOX	Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33901898]
Caco-2	IC₅₀	5 μM Compound: Doxorubicin	Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 24099994]
Caco-2	IC₅₀	5.13 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA	[PMID: 31404864]
Caco-2	IC₅₀	6.7 μM Compound: Doxorubicin	Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
Caco-2	IC₅₀	63.3 μM Compound: Doxorubicin	Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 28463785]
Caco-2	IC₅₀	64.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay	[PMID: 35526504]
Caco-2	IC₅₀	9.4 μM Compound: Doxorubicin	Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
CAKI-1	GI₅₀	0.95 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay	[PMID: 23871905]
CAKI-1	GI₅₀	0.95 μM Compound: Doxorubicin	Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
CAL-27	IC₅₀	0.18 μM Compound: DOX	Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36709571]
Calu-1	GI₅₀	< 1 x 10^-2 μM Compound: Doxorubicin	Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay	[PMID: 30071406]
Calu-1	GI₅₀	< 1 x 10^-2 μM Compound: Doxorubicin	Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
Calu-3	IC₅₀	0.11 μM Compound: DOX	Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay	[PMID: 27769032]
Calu-3	IC₅₀	0.27 μM Compound: DOX	Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay	[PMID: 27769032]
Cancer cell lines	GI₅₀	0.065 μM Compound: Doxorubicin	Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	0.065 μM Compound: Doxorubicin	Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	0.065 μM Compound: Doxorubicin	Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Caov-3 cell line	IC₅₀	< 0.1 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human Caov3 cells after 72 hrs by MTT assay Antiproliferative activity against human Caov3 cells after 72 hrs by MTT assay	[PMID: 24095089]
CAPAN-1	IC₅₀	1.7 μM Compound: Doxorubicin	Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
CAPAN-1	IC₅₀	1.7 μM Compound: Dox	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
CAPAN-1	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
carcinoma cell line	IC₅₀	< 0.01 μM Compound: doxorubicin	Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay	[PMID: 11454467]
CCD-841CoN	IC₅₀	1.5 μg/mL Compound: Doxorubicin	Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35526504]
CCRF S-180	IC₅₀	29.2 μM Compound: Doxorubicin	Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay	[PMID: 21620529]
CCRF S-180	IC₅₀	9.25 μM Compound: Doxorubicin	Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25648297]
CCRF-CEM	IC₅₀	0.003 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay	[PMID: 26260339]
CCRF-CEM	IC₅₀	0.003 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay	[PMID: 28456567]
CCRF-CEM	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
CCRF-CEM	IC₅₀	0.009 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells by resazurin assay Cytotoxicity against human CCRF-CEM cells by resazurin assay	[PMID: 24561670]
CCRF-CEM	EC₅₀	0.009 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29937978]
CCRF-CEM	IC₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 27808511]
CCRF-CEM	EC₅₀	0.015 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29887512]
CCRF-CEM	IC₅₀	0.017 μM Compound: Doxorubicin	Growth inhibition of human CCRF-CEM cells by resazurin assay Growth inhibition of human CCRF-CEM cells by resazurin assay	[PMID: 28121440]
CCRF-CEM	IC₅₀	0.017 μM Compound: Doxorubicin	Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay	[PMID: 29560715]
CCRF-CEM	IC₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 18586355]
CCRF-CEM	IC₅₀	0.02 μg/mL Compound: doxorubicin	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 15787450]
CCRF-CEM	GI₅₀	0.02 μM Compound: Doxorubicin	Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay	[PMID: 20570145]
CCRF-CEM	IC₅₀	0.02 μM Compound: Doxo	Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
CCRF-CEM	EC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 26320088]
CCRF-CEM	CC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 26119992]
CCRF-CEM	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 19053767]
CCRF-CEM	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
CCRF-CEM	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay	[PMID: 32663024]
CCRF-CEM	IC₅₀	0.03 μM Compound: doxo	Antiproliferative activity against human CCRF-CEM cell line by MTT assay Antiproliferative activity against human CCRF-CEM cell line by MTT assay	[PMID: 16913700]
CCRF-CEM	IC₅₀	0.037 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells by CCK-8 assay Cytotoxicity against human CCRF-CEM cells by CCK-8 assay	[PMID: 22884578]
CCRF-CEM	IC₅₀	0.052 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 27060757]
CCRF-CEM	IC₅₀	0.06 μM Compound: 1; Dox	Antiproliferative activity against human CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CEM cells after 72 hrs by MTT assay	[PMID: 26633734]
CCRF-CEM	IC₅₀	0.06 μM Compound: Dox	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 21144624]
CCRF-CEM	IC₅₀	0.06 μM Compound: adriamycin	Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs	[PMID: 17323939]
CCRF-CEM	GI₅₀	0.08 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay	[PMID: 23871905]
CCRF-CEM	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
CCRF-CEM	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
CCRF-CEM	IC₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
CCRF-CEM	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 19394829]
CCRF-CEM	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
CCRF-CEM	IC₅₀	0.1 mM Compound: Dox	Antiproliferative activity against human CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CEM cells after 72 hrs by MTT assay	[PMID: 29459273]
CCRF-CEM	IC₅₀	0.1 μM Compound: 2	Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 33974416]
CCRF-CEM	IC₅₀	0.1 μM Compound: Dox	Antiproliferative activity in human CEM cells after 72 hrs by MTT assay Antiproliferative activity in human CEM cells after 72 hrs by MTT assay	[PMID: 30268824]
CCRF-CEM	IC₅₀	0.1 μM Compound: 5	Antiproliferative activity against human CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CEM cells after 72 hrs by MTT assay	[PMID: 29137865]
CCRF-CEM	IC₅₀	0.11 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
CCRF-CEM	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 32496057]
CCRF-CEM	IC₅₀	0.39 μM Compound: Doxorubicin	Cytostatic activity against human CEM/0 after 72 hrs by cell counting Cytostatic activity against human CEM/0 after 72 hrs by cell counting	[PMID: 22555152]
CCRF-CEM	EC₅₀	0.4654 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	IC₅₀	0.5 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 25993619]
CCRF-CEM	IC₅₀	0.5 μM Compound: Doxo	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
CCRF-CEM	IC₅₀	1.05 μM Compound: Dox	Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay	[PMID: 29107422]
CCRF-CEM	IC₅₀	1.05 μM Compound: DOX	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay	[PMID: 29665526]
CCRF-CEM	IC₅₀	2.14 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM cells by XTT assay Cytotoxicity against human CCRF-CEM cells by XTT assay	[PMID: 22663190]
CCRF-CEM	GI₅₀	3 x 10^-2 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 30071406]
CCRF-CEM	EC₅₀	3.078 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	IC₅₀	3.14 μM Compound: Doxorubicin	Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay	[PMID: 22272829]
CCRF-CEM	IC₅₀	3.14 μM Compound: Doxorubicin	Cytotoxicity against human CEM cells after 48 hrs Cytotoxicity against human CEM cells after 48 hrs	[PMID: 20873721]
CCRF-CEM	GI₅₀	3.3 x 10^-2 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
CCRF-CEM	IC₅₀	36.9 nM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM by XTT assay Cytotoxicity against human CCRF-CEM by XTT assay	[PMID: 20527917]
CCRF-CEM	IC₅₀	45 nM Compound: Dox	Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay	[PMID: 22276998]
CCRF-CEM	IC₅₀	55.91 μM Compound: Dox	Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay	[PMID: 27687968]
CCRF-SB	EC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 26320088]
CCRF-SB	IC₅₀	0.02 μM Compound: doxo	Antiproliferative activity against human CCRF-SB cell line by MTT assay Antiproliferative activity against human CCRF-SB cell line by MTT assay	[PMID: 16913700]
CCRF-SB	IC₅₀	0.03 μM Compound: Doxo	Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
CCRF-SB	CC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 26119992]
CCRF-SB	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 19053767]
CEM/VLB100	IC₅₀	3.71 μM Compound: adriamycin	Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs	[PMID: 17323939]
CEM-VM1	IC₅₀	0.55 μM Compound: adriamycin	Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs	[PMID: 17323939]
CH1	IC₅₀	0.0063 μM Compound: Doxirubicin	Concentration required to inhibit CH1-cell growth by 50% Concentration required to inhibit CH1-cell growth by 50%	[PMID: 9703471]
CHO	IC₅₀	0.08 μM Compound: Adriamycin	Cytotoxicity against CHO cells after 72 hrs by MTT assay Cytotoxicity against CHO cells after 72 hrs by MTT assay	[PMID: 21721528]
CHO	CC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 25791675]
CHO	IC₅₀	3.6 μM Compound: Doxorubicin	Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34782182]
CHO	CC₅₀	4.65 μM Compound: Doxorubicin	Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32088496]
CHO	IC₅₀	6 μM Compound: DOX	Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line	[PMID: 9526570]
CHO	IC₅₀	6.0 x 10^-8 M Compound: DOX	Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius) Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius)	[PMID: 9526570]
CHO	IC₅₀	9.7 μM Compound: Adriamycin	Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay	[PMID: 21721528]
CHO-K1	IC₅₀	4.2 μM Compound: Doxorubicin	Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
CNE	IC₅₀	0.22 μM Compound: DOX	Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay	[PMID: 29614418]
CNE-2	IC₅₀	3.52 μM Compound: Doxorubicin	Cytotoxicity against human CNE2 cells by CCK8 assay Cytotoxicity against human CNE2 cells by CCK8 assay	[PMID: 29452840]
CNS cell	GI₅₀	94 μM Compound: doxorubicin	Cytotoxicity against human CNS cells after 48 hrs by SRB assay Cytotoxicity against human CNS cells after 48 hrs by SRB assay	[PMID: 19070942]
COLO 201	IC₅₀	0.8 μM Compound: Doxorubicin	Growth inhibition of human Colo-201 cells by MTT assay Growth inhibition of human Colo-201 cells by MTT assay	[PMID: 33901643]
COLO 205	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay	[PMID: 20673627]
COLO 205	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
COLO 205	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
COLO 205	GI₅₀	0.14 μM Compound: adriamycin	Cytotoxicity against human Colo205 cells after 24 hrs by SRB method Cytotoxicity against human Colo205 cells after 24 hrs by SRB method	[PMID: 18262426]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human COLO205 cells after 48 hrs by SRB assay Growth inhibition of human COLO205 cells after 48 hrs by SRB assay	[PMID: 20031423]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human COLO205 cells by SRB assay Growth inhibition of human COLO205 cells by SRB assay	[PMID: 22361684]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Anticancer activity against human COLO205 cells by SRB method Anticancer activity against human COLO205 cells by SRB method	[PMID: 21676506]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
COLO 205	GI₅₀	0.15 μM Compound: ADR, Adriamycin	Growth inhibition of human Colo205 cells by SRB method Growth inhibition of human Colo205 cells by SRB method	[PMID: 18207392]
COLO 205	GI₅₀	0.18 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay	[PMID: 23871905]
COLO 205	GI₅₀	0.18 μM Compound: Doxorubicin	Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
COLO 205	GI₅₀	0.18 μM Compound: Doxorubicin	Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
COLO 205	IC₅₀	0.26 μM Compound: adriamycin	Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay	[PMID: 17107806]
COLO 205	IC₅₀	0.37 μM Compound: Doxo	Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C2MD20302B
COLO 205	IC₅₀	0.4 μM Compound: Doxorubicin	Anticancer activity against human COLO205 cells by MTT assay Anticancer activity against human COLO205 cells by MTT assay	[PMID: 21570750]
COLO 205	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human COLO205 cells by MTT assay Cytotoxicity against human COLO205 cells by MTT assay	[PMID: 24300737]
COLO 205	IC₅₀	0.52 μM Compound: DOX	Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
COLO 205	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24780595]
COLO 205	IC₅₀	0.7 μM Compound: Dox	Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24507927]
COLO 205	IC₅₀	1.43 μM Compound: Doxorubicin	Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
COLO 205	IC₅₀	1.5 μM Compound: Doxorubicin	Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
COLO 205	IC₅₀	1.69 μM Compound: Dox	Anticancer activity against human COLO205 cells after 48 hrs by MTT assay Anticancer activity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 22209733]
COLO 205	GI₅₀	14.7 μM Compound: ADR	Anticancer activity against human COLO205 cells by SRB method Anticancer activity against human COLO205 cells by SRB method	[PMID: 22104151]
COLO 205	IC₅₀	2 μM Compound: ADR	Cytotoxicity against human Colo205 cells by SRB assay Cytotoxicity against human Colo205 cells by SRB assay	[PMID: 18656370]
COLO 205	IC₅₀	2 μM Compound: ADR	Cytotoxicity against human Colo205 cells by sulforhodamine B assay Cytotoxicity against human Colo205 cells by sulforhodamine B assay	[PMID: 17822905]
COLO 205	IC₅₀	2.1 μM Compound: Doxorubicin	Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay	[PMID: 34838335]
COLO 205	IC₅₀	2.5 μM Compound: Doxorubicin	Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35293752]
COLO 205	IC₅₀	3.8 μM Compound: DOX	Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 31589431]
COLO 320	IC₅₀	7.4 μM Compound: Doxorubicin	Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35293752]
COR-L23	IC₅₀	20.1 nM Compound: Doxorubicin	Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line	[PMID: 11806724]
COS-7	IC₅₀	2.05 μM Compound: Doxorubicin	Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay	[PMID: 31404864]
COS-7	IC₅₀	3.04 μM Compound: Doxorubicin	Growth inhibition of African green monkey COS7 cells by MTT assay Growth inhibition of African green monkey COS7 cells by MTT assay	[PMID: 28147307]
CRL-7065 cell line	EC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay	[PMID: 26320088]
CWR22R	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 34851111]
CWR22R	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay	[PMID: 28617598]
CWR22R	IC₅₀	6.32 μM Compound: Doxorubicin	Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay	[PMID: 30072225]
DA-3 cell line	IC₅₀	4 μM Compound: DOX	Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay	[PMID: 24900668]
Daoy	GI₅₀	0.016 μM Compound: Doxorubicin	Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 30360625]
Daoy	IC₅₀	0.0629 μM Compound: Doxorubicin	Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34325324]
Daoy	IC₅₀	8.8 nM Compound: 5; Dox	Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay	[PMID: 31347843]
Daudi	IC₅₀	0.127 μM Compound: Dox	Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay	[PMID: 25998504]
Daudi	IC₅₀	0.3 μM Compound: adriamycin	Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay	[PMID: 17993275]
Detroit 562	IC₅₀	1.26 μM Compound: Doxorubicin	Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
DLD-1	ED₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human DLD1 cells after 3 days by MTT assay Cytotoxicity against human DLD1 cells after 3 days by MTT assay	[PMID: 16252910]
DLD-1	IC₅₀	0.1 μM Compound: adriamycin	Antitumor activity against human DLD1 cells by methylene blue staining method Antitumor activity against human DLD1 cells by methylene blue staining method	[PMID: 17656091]
DLD-1	ED₅₀	0.57 μg/mL Compound: Doxorubicin	Cytotoxicity against human DLD1 cells by MTT assay Cytotoxicity against human DLD1 cells by MTT assay	[PMID: 15104488]
DLD-1	IC₅₀	0.84 μM Compound: Dox	Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay	[PMID: 25247771]
DLD-1	IC₅₀	10.2 μM Compound: Doxorubicin	Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 30772606]
DLD-1	IC₅₀	145 nM Compound: Doxorubicin	Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
DLD-1	IC₅₀	2.6 μM Compound: Doxorubicin	Cytotoxicity against human DLD1 cells by Alamar Blue assay Cytotoxicity against human DLD1 cells by Alamar Blue assay	[PMID: 27536968]
DLD-1	IC₅₀	2.78 μM Compound: Doxorubicin	Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay	[PMID: 28159416]
DLD-1	IC₅₀	2.78 μM Compound: Doxorubicin	Cytotoxicity against human DLD1 cells by Alamar blue assay Cytotoxicity against human DLD1 cells by Alamar blue assay	[PMID: 27256910]
DU-145	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	10.1039/C6MD00097E
DU-145	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition in human DU145 cells after 48 hrs by SRB assay Growth inhibition in human DU145 cells after 48 hrs by SRB assay	[PMID: 31546197]
DU-145	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay	[PMID: 21794959]
DU-145	IC₅₀	< 2.94 μM Compound: Doxorubicin	Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay	[PMID: 20810194]
DU-145	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay	[PMID: 25059501]
DU-145	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
DU-145	IC₅₀	0.051 μM Compound: DOX	Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
DU-145	GI₅₀	0.06 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells after 72 hrs by SRB assay Growth inhibition of human DU145 cells after 72 hrs by SRB assay	[PMID: 18585035]
DU-145	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
DU-145	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 19361894]
DU-145	GI₅₀	0.1081 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 31534659]
DU-145	GI₅₀	0.11 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 23871905]
DU-145	GI₅₀	0.11 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
DU-145	GI₅₀	0.11 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
DU-145	IC₅₀	0.12 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay	[PMID: 25799376]
DU-145	IC₅₀	0.13 μM Compound: doxorubicin	Cytotoxicity against human DU145 cells by SRB microtiter plate assay Cytotoxicity against human DU145 cells by SRB microtiter plate assay	[PMID: 17585747]
DU-145	GI₅₀	0.134 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
DU-145	IC₅₀	0.153 μM Compound: Dox	Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108718]
DU-145	IC₅₀	0.2 μM Compound: DOX	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 23218718]
DU-145	IC₅₀	0.2 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 24095089]
DU-145	EC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 96 hrs by MTT assay Cytotoxicity against human DU145 cells after 96 hrs by MTT assay	[PMID: 26320088]
DU-145	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
DU-145	GI₅₀	0.35 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells after 2 days by MTT assay Growth inhibition of human DU145 cells after 2 days by MTT assay	[PMID: 20138760]
DU-145	IC₅₀	0.363 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 30654238]
DU-145	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 30660827]
DU-145	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25655719]
DU-145	IC₅₀	0.52 μM Compound: adriamycin	Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay	[PMID: 25936262]
DU-145	IC₅₀	0.53 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
DU-145	IC₅₀	0.534 μM Compound: 1	Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
DU-145	IC₅₀	0.58 μM Compound: Doxo	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 21885273]
DU-145	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 26586599]
DU-145	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 25172418]
DU-145	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 24300737]
DU-145	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy	[PMID: 28615134]
DU-145	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay	[PMID: 27187861]
DU-145	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay	[PMID: 26774921]
DU-145	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay	[PMID: 26646219]
DU-145	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 25241926]
DU-145	IC₅₀	0.86 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay	[PMID: 25481396]
DU-145	IC₅₀	0.86 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 22318164]
DU-145	IC₅₀	0.895 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28462842]
DU-145	IC₅₀	0.95 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days by CCK8 assay Cytotoxicity against human DU145 cells after 2 days by CCK8 assay	[PMID: 26361737]
DU-145	GI₅₀	0.95 μM Compound: Doxorubicin	Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
DU-145	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 21601964]
DU-145	IC₅₀	1.08 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 26948541]
DU-145	IC₅₀	1.1 μM Compound: Doxorubicin	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay	[PMID: 33540356]
DU-145	IC₅₀	1.1 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
DU-145	IC₅₀	1.3 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells after 48 hrs by MTT assay Anticancer activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 25615796]
DU-145	IC₅₀	1.38 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 26264845]
DU-145	IC₅₀	1.4 μM Compound: Doxorubicin	Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
DU-145	IC₅₀	1.41 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27015609]
DU-145	IC₅₀	1.428 μM Compound: Doxorubicin	Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay	[PMID: 27744185]
DU-145	IC₅₀	1.57 μM Compound: ADR	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22819942]
DU-145	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
DU-145	IC₅₀	1.622 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
DU-145	IC₅₀	1.75 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 21115246]
DU-145	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
DU-145	IC₅₀	1.807 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29501940]
DU-145	IC₅₀	1.82 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26708114]
DU-145	IC₅₀	1.86 μM Compound: II	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29289881]
DU-145	IC₅₀	1.9 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 4 days by MTT assay Cytotoxicity against human DU145 cells after 4 days by MTT assay	[PMID: 21704436]
DU-145	IC₅₀	1.909 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 26301558]
DU-145	IC₅₀	1.91 μM Compound: Doxorubicin	Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay	[PMID: 28923381]
DU-145	IC₅₀	1.94 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26330077]
DU-145	IC₅₀	10.86 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 22818039]
DU-145	IC₅₀	12.3 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 21429743]
DU-145	IC₅₀	13.24 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 22687747]
DU-145	IC₅₀	17.67 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells by MTT assay Anticancer activity against human DU145 cells by MTT assay	[PMID: 25743216]
DU-145	IC₅₀	2.13 μM Compound: Doxo	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29129513]
DU-145	IC₅₀	2.4 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells by MTT assay Anticancer activity against human DU145 cells by MTT assay	10.1039/C4MD00219A
DU-145	IC₅₀	2.4 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
DU-145	IC₅₀	2.45 μM Compound: Doxo (I)	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	10.1039/C4MD00228H
DU-145	IC₅₀	2.49 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26542964]
DU-145	IC₅₀	2.54 μM Compound: DOX	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
DU-145	IC₅₀	2.68 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay	[PMID: 24013413]
DU-145	IC₅₀	23.48 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 22276650]
DU-145	IC₅₀	3.11 μM Compound: Doxorubicin	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
DU-145	IC₅₀	3.11 μM Compound: DOX	Cytotoxicity against human DU145 cells after 48 hrs by SRB method Cytotoxicity against human DU145 cells after 48 hrs by SRB method	[PMID: 25933593]
DU-145	IC₅₀	3.27 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 72 hrs by XTT assay Cytotoxicity against human DU145 cells after 72 hrs by XTT assay	10.1007/s00044-013-0558-8
DU-145	IC₅₀	3.9 nM Compound: doxorubicin	Anticancer activity against human DU145 cells after 72 hrs by XTT assay Anticancer activity against human DU145 cells after 72 hrs by XTT assay	[PMID: 18829316]
DU-145	IC₅₀	4.06 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 25462233]
DU-145	IC₅₀	4.75 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 26907155]
DU-145	IC₅₀	4.8 μM Compound: DOX	Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 31589431]
DU-145	IC₅₀	4.88 μM Compound: Dox	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 24904965]
DU-145	IC₅₀	5.3 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25594739]
DU-145	IC₅₀	5.4 μM Compound: DX	Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay	10.1039/C5MD00513B
DU-145	IC₅₀	5.8 μM Compound: DXR	Cytotoxicity against human androgen-independent DU145 cells by MTT assay Cytotoxicity against human androgen-independent DU145 cells by MTT assay	[PMID: 22326399]
DU-145	IC₅₀	6 μM Compound: doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 23748152]
DU-145	IC₅₀	6.24 μM Compound: Doxo	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 21885273]
DU-145	IC₅₀	8.19 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 24607876]
EA.hy 926	IC₅₀	4.2 μM Compound: Doxorubicin	Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
EBC-1	IC₅₀	305.1 nM Compound: Doxorubicin	Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay	[PMID: 28412159]
ECa-109 cell line	IC₅₀	2.06 μM Compound: Doxorubicin	Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
Ehrlich	IC₅₀	> 10 μM Compound: doxorubicin	Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay	[PMID: 18281125]
Ehrlich	IC₅₀	> 10 μM Compound: doxorubicin	Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay	[PMID: 17400463]
Ehrlich	IC₅₀	0.35 μM Compound: Doxorubicin	Cytotoxicity against mouse EAC after 3 days by MTT assay Cytotoxicity against mouse EAC after 3 days by MTT assay	[PMID: 8350087]
Ehrlich	IC₅₀	37.4 μg/mL Compound: Doxorubicin	Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay	[PMID: 27894044]
Ehrlich	IC₅₀	37.5 μg/mL Compound: Doxorubicin	Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test	[PMID: 20149941]
Ehrlich	IC₅₀	38 μg/mL Compound: Doxorubicin	Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test	[PMID: 21112675]
Ehrlich	IC₅₀	38 μg/mL Compound: doxorubicin	Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion	[PMID: 19944497]
Ehrlich	IC₅₀	4.18 μM Compound: doxorubicin	Cytotoxicity against mouse EAC after 24 hrs by MTT assay Cytotoxicity against mouse EAC after 24 hrs by MTT assay	[PMID: 19128861]
Ehrlich	IC₅₀	5.22 μM Compound: Doxorubicin	Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay	[PMID: 22542958]
Ehrlich	IC₅₀	52 μg/mL Compound: Doxorubicin	Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay	[PMID: 19853327]
Ehrlich	IC₅₀	69.9 μM Compound: Doxorubicin	Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay	[PMID: 20413187]
EKVX	GI₅₀	0.41 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human EKVX cells after 48 hrs by SRB assay Cytotoxicity against human EKVX cells after 48 hrs by SRB assay	[PMID: 23871905]
EKVX	GI₅₀	0.41 μM Compound: Doxorubicin	Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
EKVX	GI₅₀	0.41 μM Compound: Doxorubicin	Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
EL4	IC₅₀	0.67 μg/mL Compound: (20) adriamycin	In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay	[PMID: 12620075]
EMT6	ED₅₀	< 0.0001 μM Compound: Adriamycin	Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition. Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.	[PMID: 7452674]
EMT6	ED₅₀	0.012 μM Compound: Adriamycin	Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition. Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.	[PMID: 7452674]
EOL1	IC₅₀	0.001269 μM Compound: Doxorubicin	Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay	[PMID: 30540463]
Epithelial cell	IC₅₀	9.787 nM Compound: Doxorubicin	Cytotoxicity against albino rat epithelial rat by MTT assay Cytotoxicity against albino rat epithelial rat by MTT assay	[PMID: 34116327]
Erythrocyte	EC₅₀	> 200 μg/mL Compound: Dox	Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry	[PMID: 25147145]
Erythrocyte	EC₅₀	> 50 μg/mL Compound: DOXO	Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry	[PMID: 19947600]
F460pv8/eto	IC₅₀	0.02 μM Compound: Doxorubicin	Inhibitory activity against F460pv8/eto cell line using MTT assay Inhibitory activity against F460pv8/eto cell line using MTT assay	[PMID: 10780913]
FaDu	IC₅₀	0.16 μM Compound: DOX	Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36709571]
FaDu	IC₅₀	0.68 μM Compound: Doxorubicin	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
Fibroblast	IC₅₀	0.005 μM Compound: Doxorubicin	Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Fibroblast	IC₅₀	0.015 μM Compound: Doxorubicine	Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Fibroblast	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
Fibroblast	IC₅₀	0.03 μM Compound: Doxorubicin	Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
Fibroblast	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
Fibroblast	IC₅₀	1.3 x 10^-11 μM Compound: Doxo	Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay	[PMID: 25468043]
Fibroblast	IC₅₀	67 μM Compound: Doxorubicin	Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
Fibroblast	IC₅₀	7.86 μM Compound: Doxorubicin	Antiproliferative activity against human dermal fibroblast cells after 72 hrs Antiproliferative activity against human dermal fibroblast cells after 72 hrs	[PMID: 25127463]
G-361	GI₅₀	< 1 x 10^-1 μM Compound: ADR	Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay	10.1007/s00044-012-0084-0
G-361	IC₅₀	0.09 μM Compound: Doxo	Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
G-361	IC₅₀	0.09 μM Compound: doxo	Antiproliferative activity against human G361 cell line by MTT assay Antiproliferative activity against human G361 cell line by MTT assay	[PMID: 16913700]
GES1	IC₅₀	0.53 μM Compound: ADM	Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay	[PMID: 25462264]
GOTO	IC₅₀	4.73 nM Compound: Doxorubicin	Cytotoxicity against human GOTO cells after 3 days by MTT assay Cytotoxicity against human GOTO cells after 3 days by MTT assay	[PMID: 20356655]
GOTO	IC₅₀	4.73 nM Compound: Doxorubicin	Cytotoxicity against human GOTO cells by MTT assay Cytotoxicity against human GOTO cells by MTT assay	[PMID: 19345581]
H22	IC₅₀	36.51 μM Compound: Doxorubicin	Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay	[PMID: 21620529]
H69AR	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay	[PMID: 36734533]
HA22T cell line	IC₅₀	0.31 μM Compound: adriamycin	Cytotoxicity against human HA22T cells after 72 hrs by MTT assay Cytotoxicity against human HA22T cells after 72 hrs by MTT assay	[PMID: 17107806]
HaCaT	GI₅₀	< 0.025 μg/mL Compound: DOX; Doxo	Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay	[PMID: 26859070]
HaCaT	GI₅₀	< 0.046 μM Compound: Dox	Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
HaCaT	GI₅₀	< 0.046 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay	[PMID: 33214037]
HaCaT	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay	[PMID: 31596585]
HaCaT	IC₅₀	0.03 μM Compound: Dox	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
HaCaT	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
HaCaT	GI₅₀	0.11 μg/mL Compound: DOX	Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
HaCaT	GI₅₀	0.2 μM Compound: Dox	Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
HaCaT	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31753514]
HaCaT	IC₅₀	0.235 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31383628]
HaCaT	IC₅₀	0.29 μM Compound: DOX	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
HaCaT	IC₅₀	0.52 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30389295]
HaCaT	IC₅₀	0.53 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26934105]
HaCaT	GI₅₀	0.64 μM Compound: Dox	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
HaCaT	GI₅₀	0.9 μM Compound: Dox	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HaCaT	GI₅₀	0.9 μM Compound: Dox	Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HaCaT	IC₅₀	1.09 μM Compound: Dox	Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30031974]
HaCaT	IC₅₀	3.26 μg/mL Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay	[PMID: 24269165]
HaCaT	IC₅₀	50 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay	[PMID: 35271771]
HBL-100	IC₅₀	0.08 μM Compound: Doxorubicin	Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay	[PMID: 29471119]
HBL-100	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay	[PMID: 19361894]
HBL-100	IC₅₀	8.5 μM Compound: Doxorubicin	Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay	[PMID: 29471119]
HCC 2998	GI₅₀	0.26 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay	[PMID: 23871905]
HCC 2998	GI₅₀	0.26 μM Compound: Doxorubicin	Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HCC 2998	GI₅₀	0.26 μM Compound: Doxorubicin	Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HCC1937	IC₅₀	0.44 μM Compound: Doxorubicin	Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay	[PMID: 29407962]
HCC1954	IC₅₀	0.045 μM Compound: DOX	Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
HCC70	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
HCT-116	GI₅₀	< 1 μM Compound: DOX	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	[PMID: 31990554]
HCT-116	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human HCT-116 cells by SRB assay Cytotoxicity against human HCT-116 cells by SRB assay	[PMID: 33847126]
HCT-116	IC₅₀	> 8 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 31836446]
HCT-116	IC₅₀	0.007 ug Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay	[PMID: 27393950]
HCT-116	IC₅₀	0.007 μM Compound: DOX	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27668963]
HCT-116	IC₅₀	0.01 μM Compound: DOX	Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay	[PMID: 31431364]
HCT-116	GI₅₀	0.011 μM Compound: Doxorubicin	Cytostatic activity against human HCT116 cells after 5 days by SRB assay Cytostatic activity against human HCT116 cells after 5 days by SRB assay	[PMID: 21711054]
HCT-116	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	10.1039/C4MD00371C
HCT-116	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
HCT-116	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
HCT-116	IC₅₀	0.023 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 31264855]
HCT-116	GI₅₀	0.023 μM Compound: Doxorubicin	Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line	[PMID: 11755363]
HCT-116	IC₅₀	0.037 μM Compound: adriamycin	Antitumor activity against human HCT116 cells by methylene blue staining method Antitumor activity against human HCT116 cells by methylene blue staining method	[PMID: 17656091]
HCT-116	IC₅₀	0.05 μM Compound: Doxorubicine	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
HCT-116	IC₅₀	0.05 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
HCT-116	IC₅₀	0.069 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25462279]
HCT-116	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27060757]
HCT-116	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 20846862]
HCT-116	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27448912]
HCT-116	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24780599]
HCT-116	GI₅₀	0.08 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 23871905]
HCT-116	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HCT-116	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HCT-116	IC₅₀	0.08 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
HCT-116	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21215623]
HCT-116	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay	[PMID: 32755677]
HCT-116	IC₅₀	0.1 mM Compound: Dox	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29459273]
HCT-116	IC₅₀	0.1 μM Compound: DOX	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay	[PMID: 31784322]
HCT-116	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
HCT-116	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
HCT-116	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30659997]
HCT-116	IC₅₀	0.1 μM Compound: 5	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29137865]
HCT-116	IC₅₀	0.1 μM Compound: 1; Dox	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26890118]
HCT-116	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27016707]
HCT-116	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
HCT-116	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
HCT-116	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31836446]
HCT-116	IC₅₀	0.11 μM Compound: 1; Dox	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26633734]
HCT-116	IC₅₀	0.11 μM Compound: Dox	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 21144624]
HCT-116	IC₅₀	0.12 μM Compound: Doxorubicin	Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
HCT-116	GI₅₀	0.13 μM Compound: Doxorubicine	Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay	[PMID: 20045222]
HCT-116	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
HCT-116	IC₅₀	0.15 μM Compound: DOXO	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
HCT-116	GI₅₀	0.15 μM Compound: Adriamycin	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24686011]
HCT-116	GI₅₀	0.15 μM Compound: Adriamycin	Growth inhibition of human HCT116 cells by sulforhodamine B assay Growth inhibition of human HCT116 cells by sulforhodamine B assay	[PMID: 24650643]
HCT-116	EC₅₀	0.16 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35567964]
HCT-116	IC₅₀	0.16 μM Compound: Dx	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
HCT-116	IC₅₀	0.18 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26280922]
HCT-116	IC₅₀	0.18 μM Compound: Dox	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25998504]
HCT-116	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 28055219]
HCT-116	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 36044031]
HCT-116	IC₅₀	0.2 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
HCT-116	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human HCT116 cells by SRB method Cytotoxicity against human HCT116 cells by SRB method	[PMID: 29144133]
HCT-116	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 26561719]
HCT-116	IC₅₀	0.2 μM Compound: ADM	Cytotoxic activity against human HCT116 cells by SRB method Cytotoxic activity against human HCT116 cells by SRB method	[PMID: 25611519]
HCT-116	IC₅₀	0.21 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34778772]
HCT-116	IC₅₀	0.21 μM Compound: Dox	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33479619]
HCT-116	IC₅₀	0.21 μM Compound: DOX	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
HCT-116	IC₅₀	0.21 μM Compound: DOXO	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28818447]
HCT-116	IC₅₀	0.21 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24370114]
HCT-116	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31836446]
HCT-116	IC₅₀	0.221 μM Compound: Dox	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108718]
HCT-116	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay	[PMID: 24398294]
HCT-116	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay	[PMID: 29317147]
HCT-116	IC₅₀	0.25 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay	[PMID: 31679979]
HCT-116	IC₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay	[PMID: 25163667]
HCT-116	IC₅₀	0.27 μM Compound: DOX	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31999451]
HCT-116	IC₅₀	0.286 μg/mL Compound: DOX	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20722446]
HCT-116	IC₅₀	0.29 μM Compound: DOX	Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	EC₅₀	0.29 μM Compound: Doxorubicin	Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs	[PMID: 19282188]
HCT-116	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay	[PMID: 31403289]
HCT-116	IC₅₀	0.3 μM Compound: Dox	Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 34902732]
HCT-116	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 22749279]
HCT-116	IC₅₀	0.31 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28327308]
HCT-116	IC₅₀	0.31 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27886545]
HCT-116	IC₅₀	0.33 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay	[PMID: 27521588]
HCT-116	IC₅₀	0.34 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 33261897]
HCT-116	IC₅₀	0.34 μM Compound: Doxorubicin	Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
HCT-116	IC₅₀	0.34 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay	[PMID: 31158748]
HCT-116	IC₅₀	0.34 μM Compound: DOXO	Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay	[PMID: 26890119]
HCT-116	IC₅₀	0.34 μM Compound: Dox	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 25247771]
HCT-116	IC₅₀	0.34 μM Compound: DOX	Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 27080182]
HCT-116	IC₅₀	0.38 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay	[PMID: 31158748]
HCT-116	IC₅₀	0.38 μM Compound: DOXO	Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay	[PMID: 26890119]
HCT-116	IC₅₀	0.38 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 26947606]
HCT-116	GI₅₀	0.4 μM Compound: Doxorubicin	Growth inhibition of human HCT116 cells after 2 days by MTT assay Growth inhibition of human HCT116 cells after 2 days by MTT assay	[PMID: 20570145]
HCT-116	IC₅₀	0.4 μM Compound: DOX	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30429098]
HCT-116	IC₅₀	0.4 μM Compound: Dox	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 21983438]
HCT-116	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	10.1039/C0MD00219D
HCT-116	IC₅₀	0.41 μM Compound: adriamycin	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 17125240]
HCT-116	IC₅₀	0.467 μM Compound: Doxorubicin	Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay	[PMID: 35694689]
HCT-116	IC₅₀	0.477 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25703298]
HCT-116	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30783501]
HCT-116	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
HCT-116	IC₅₀	0.5 mM Compound: Dox	Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay	[PMID: 29459273]
HCT-116	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay	[PMID: 28494255]
HCT-116	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
HCT-116	IC₅₀	0.5 μM Compound: 5	Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay	[PMID: 29137865]
HCT-116	IC₅₀	0.5 μM Compound: 1; Dox	Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay	[PMID: 26890118]
HCT-116	GI₅₀	0.5 μM Compound: Dox	Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HCT-116	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay	[PMID: 26222449]
HCT-116	IC₅₀	0.52 μM Compound: Dox	Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay	[PMID: 21144624]
HCT-116	IC₅₀	0.55 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	GI₅₀	0.57 μM Compound: Dox	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
HCT-116	IC₅₀	0.579 μM Compound: 1	Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
HCT-116	GI₅₀	0.6 μM Compound: Dox	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HCT-116	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
HCT-116	IC₅₀	0.6 μM Compound: Dox	Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay	[PMID: 30659997]
HCT-116	IC₅₀	0.62 μM Compound: doxorubicin	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 17194596]
HCT-116	IC₅₀	0.63 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 23291120]
HCT-116	IC₅₀	0.65 μg/mL Compound: Dox	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 20399544]
HCT-116	IC₅₀	0.7 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
HCT-116	IC₅₀	0.74 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26874404]
HCT-116	GI₅₀	0.76 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HCT-116	IC₅₀	0.79 μM Compound: DOX	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
HCT-116	IC₅₀	0.8 μM Compound: Dox	Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 34902732]
HCT-116	IC₅₀	0.87 μM Compound: DOX	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HCT-116	IC₅₀	1.01 μM Compound: Doxorubicin	Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 28923381]
HCT-116	IC₅₀	1.01 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28554092]
HCT-116	IC₅₀	1.1 μM Compound: DOX	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay	[PMID: 34323485]
HCT-116	IC₅₀	1.19 μM Compound: Dox	Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay	10.1007/s00044-012-0057-3
HCT-116	IC₅₀	1.23 μM Compound: Doxorubicin	Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay	[PMID: 28554092]
HCT-116	IC₅₀	1.3 μg/mL Compound: Doxorubicin, Adriablastina	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method	[PMID: 21664013]
HCT-116	IC₅₀	1.38 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 24182355]
HCT-116	IC₅₀	1.4 μM Compound: 1, DOX	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25244612]
HCT-116	IC₅₀	1.4 μM Compound: I	Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test	[PMID: 17276690]
HCT-116	IC₅₀	1.6 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells by MTT assay Cytotoxicity against human HCT-116 cells by MTT assay	[PMID: 36325400]
HCT-116	IC₅₀	1.78 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
HCT-116	IC₅₀	1.878 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
HCT-116	IC₅₀	1.96 μM Compound: DOX	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 30245395]
HCT-116	IC₅₀	1.96 μM Compound: DOX	Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay	[PMID: 30071408]
HCT-116	IC₅₀	1.96 μM Compound: DOX	Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
HCT-116	IC₅₀	19.7 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 32771798]
HCT-116	IC₅₀	19.9 nM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay	[PMID: 25499433]
HCT-116	IC₅₀	2.05 μM Compound: DOX	Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	IC₅₀	2.2 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 hrs by WST assay Cytotoxicity against human HCT116 cells after 24 hrs by WST assay	[PMID: 25881821]
HCT-116	IC₅₀	2.38 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells by WST-8 assay Cytotoxicity against human HCT116 cells by WST-8 assay	[PMID: 29295796]
HCT-116	IC₅₀	2.4 μM Compound: Doxorubicin	Anticancer activity against human HCT-116 cells by MTT assay Anticancer activity against human HCT-116 cells by MTT assay	[PMID: 33421712]
HCT-116	IC₅₀	2.56 μM Compound: doxorubicin	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	10.1007/s00044-013-0795-x
HCT-116	IC₅₀	2.6 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 31200236]
HCT-116	GI₅₀	21.4 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay	[PMID: 27614919]
HCT-116	IC₅₀	22 nM Compound: doxorubicine	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 23072299]
HCT-116	IC₅₀	22 nM Compound: Doxorubicine	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 21142180]
HCT-116	IC₅₀	3.29 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs	[PMID: 34530384]
HCT-116	IC₅₀	3.3 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay	[PMID: 20813435]
HCT-116	IC₅₀	3.36 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
HCT-116	IC₅₀	3.7 μM Compound: Dox	Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay	[PMID: 26706352]
HCT-116	IC₅₀	3.73 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 21723735]
HCT-116	IC₅₀	366 nM Compound: DOX	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30878835]
HCT-116	IC₅₀	4.4 μM Compound: 1, DOX	Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay	[PMID: 25244612]
HCT-116	IC₅₀	4.4 μM Compound: I	Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test	[PMID: 17276690]
HCT-116	IC₅₀	4.8 μM Compound: Doxorubicin	Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay	[PMID: 27112448]
HCT-116	IC₅₀	49.5 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay	[PMID: 35271771]
HCT-116	IC₅₀	5 mM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 23685942]
HCT-116	IC₅₀	5 mM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22440624]
HCT-116	IC₅₀	5.1 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34530384]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32085964]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 30015070]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HCT-116	IC₅₀	5.23 μM Compound: Dox	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32527460]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay	[PMID: 35964425]
HCT-116	IC₅₀	5.23 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34126285]
HCT-116	IC₅₀	5.23 μM Compound: Doxorubicin	Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay	[PMID: 33065442]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	[PMID: 30216848]
HCT-116	IC₅₀	5.95 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay	[PMID: 20303768]
HCT-116	IC₅₀	56.6 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay	[PMID: 33016067]
HCT-116	IC₅₀	57.77 nM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay	[PMID: 34795858]
HCT-116	IC₅₀	6 nM Compound: doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 19655762]
HCT-116	IC₅₀	6.3 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 27894044]
HCT-116	IC₅₀	6.86 μM Compound: Doxorubicin	Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay	10.1007/s00044-013-0497-4
HCT-116	IC₅₀	6.86 μM Compound: DOX	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 22444025]
HCT-116	IC₅₀	6.86 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 22119132]
HCT-116	IC₅₀	6.86 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 22119131]
HCT-116	IC₅₀	7.41 μM Compound: Dox	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35635947]
HCT-116	IC₅₀	7.7 μM Compound: adriamycin	Cytotoxicity against human HCT116 cells after 4 days by MTT assay Cytotoxicity against human HCT116 cells after 4 days by MTT assay	[PMID: 17194586]
HCT-116	GI₅₀	70 nM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay	10.1039/C0MD00179A
HCT-116	IC₅₀	761.45 nM Compound: Doxorubicin	Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay	[PMID: 34116327]
HCT-116	IC₅₀	8.07 μM Compound: Cpd I	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33360576]
HCT-116	IC₅₀	8.29 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay	[PMID: 30096580]
HCT-116	IC₅₀	8.29 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay	[PMID: 32361329]
HCT-116	IC₅₀	8.7 μM Compound: ADR	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	10.1039/C2MD20270K
HCT-116	IC₅₀	8.7 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30660827]
HCT-116	IC₅₀	8.8 nM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay	[PMID: 30660827]
HCT-116	IC₅₀	80 nM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 35213166]
HCT-116	IC₅₀	810 nM Compound: DX	Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr	[PMID: 15456268]
HCT-116	IC₅₀	9.4 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31323616]
HCT-116	IC₅₀	9.63 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33214036]
HCT-116	IC₅₀	9.74 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 28489373]
HCT-15	GI₅₀	< 10 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	10.1039/C5MD00224A
HCT-15	IC₅₀	> 1000 nM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 20690624]
HCT-15	ED₅₀	0.006 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by sulforhodamine B method Cytotoxicity against human HCT15 cells by sulforhodamine B method	[PMID: 12193011]
HCT-15	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
HCT-15	IC₅₀	0.01 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by MTT assay Cytotoxicity against human HCT15 cells by MTT assay	[PMID: 17764956]
HCT-15	IC₅₀	0.02 μg/mL Compound: doxorubicin	Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay	[PMID: 19342127]
HCT-15	IC₅₀	0.025 μM Compound: 1 (Doxorubicin)	In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay	[PMID: 14980672]
HCT-15	IC₅₀	0.028 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 20719504]
HCT-15	IC₅₀	0.035 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 22483395]
HCT-15	IC₅₀	0.037 μM Compound: Doxorubicin	Anticancer activity against human HCT15 cells by sulforhodamine B assay Anticancer activity against human HCT15 cells by sulforhodamine B assay	[PMID: 19819696]
HCT-15	IC₅₀	0.038 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 20594848]
HCT-15	ED₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 11325244]
HCT-15	ED₅₀	0.05 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 15921415]
HCT-15	IC₅₀	0.05 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by sulforhodamine B assay Cytotoxicity against human HCT15 cells by sulforhodamine B assay	[PMID: 21684168]
HCT-15	ED₅₀	0.071 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 19783438]
HCT-15	GI₅₀	0.076 μM Compound: ADR	Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method	[PMID: 34500188]
HCT-15	GI₅₀	0.077 μM Compound: ADR	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30253887]
HCT-15	GI₅₀	0.077 μM Compound: ADR	Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 28870801]
HCT-15	IC₅₀	0.08 μg/mL Compound: adriamycin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 15921426]
HCT-15	IC₅₀	0.082 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 22951040]
HCT-15	GI₅₀	0.0854 μM Compound: ADR	Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay	[PMID: 27096046]
HCT-15	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay	[PMID: 24215890]
HCT-15	IC₅₀	0.1 μM Compound: Doxorubicin	In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay	[PMID: 9873661]
HCT-15	IC₅₀	0.1077 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay	[PMID: 25098650]
HCT-15	IC₅₀	0.109 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
HCT-15	IC₅₀	0.129 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 25466198]
HCT-15	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay	[PMID: 23634786]
HCT-15	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by sulforhodamine B assay Cytotoxicity against human HCT15 cells by sulforhodamine B assay	[PMID: 23815260]
HCT-15	IC₅₀	0.164 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 19435339]
HCT-15	ED₅₀	0.164 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 18314958]
HCT-15	GI₅₀	0.19 μM Compound: Doxorubicin	Antiproliferative activity against human HCT15 cells by SRB assay Antiproliferative activity against human HCT15 cells by SRB assay	[PMID: 19394218]
HCT-15	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28641156]
HCT-15	IC₅₀	0.225 μM Compound: Doxorubicin	Anticancer activity against human HCT15 cells after 48 hrs by SRB assay Anticancer activity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 17070967]
HCT-15	IC₅₀	0.23 μM Compound: Doxorubicine	Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay	[PMID: 12039588]
HCT-15	IC₅₀	0.251 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells after 3 days by SRB assay Cytotoxicity against human HCT15 cells after 3 days by SRB assay	[PMID: 18321715]
HCT-15	IC₅₀	0.27 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs Cytotoxicity against human HCT15 cells after 48 hrs	[PMID: 17673337]
HCT-15	ED₅₀	0.35 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB method Cytotoxicity against human HCT15 cells by SRB method	[PMID: 16252909]
HCT-15	GI₅₀	0.45 μM Compound: ADR	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 25953156]
HCT-15	IC₅₀	0.6 μM Compound: Doxorubicin	Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay	[PMID: 18063366]
HCT-15	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 20176479]
HCT-15	IC₅₀	0.872 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay	[PMID: 27856237]
HCT-15	IC₅₀	1.03 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
HCT-15	IC₅₀	1.08 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay	[PMID: 26361737]
HCT-15	IC₅₀	1.08 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay	[PMID: 25481396]
HCT-15	IC₅₀	1.13 μM Compound: DOX	Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
HCT-15	IC₅₀	1.2 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 21601964]
HCT-15	IC₅₀	1.23 μM Compound: adriamycin	Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay	[PMID: 25936262]
HCT-15	IC₅₀	1.25 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells by MTT assay Cytotoxicity against human HCT15 cells by MTT assay	[PMID: 21115246]
HCT-15	IC₅₀	1.28 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 22318164]
HCT-15	GI₅₀	1.34 μM Compound: ADR	Antiproliferative activity against human HCT15 cells by SRB method Antiproliferative activity against human HCT15 cells by SRB method	[PMID: 24835787]
HCT-15	GI₅₀	1.34 μM Compound: ADR	Antiproliferative activity against human HCT15 cells by SRB assay Antiproliferative activity against human HCT15 cells by SRB assay	[PMID: 22738641]
HCT-15	IC₅₀	1.38 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay	[PMID: 24013413]
HCT-15	GI₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 23964644]
HCT-15	GI₅₀	1.64 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 19596579]
HCT-15	IC₅₀	1.67 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 17827007]
HCT-15	IC₅₀	1.67 μM Compound: Doxorubicin	Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay. Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay.	[PMID: 14643344]
HCT-15	IC₅₀	1.76 μM Compound: ADR	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 22819942]
HCT-15	ED₅₀	1.8 μg/mL Compound: adriamycin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	10.1021/np960188t
HCT-15	IC₅₀	16.4 nM Compound: Doxorubicin	Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay	[PMID: 31655432]
HCT-15	IC₅₀	2.2 μM Compound: DOX	Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 30429098]
HCT-15	ED₅₀	2.4 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 9392887]
HCT-15	IC₅₀	3.33 μM Compound: DOX	Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay	[PMID: 26334499]
HCT-15	IC₅₀	3.76 μM Compound: Dox	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 24904965]
HCT-15	IC₅₀	5 nM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 22858298]
HCT-15	GI₅₀	6.46 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 23871905]
HCT-15	GI₅₀	6.46 μM Compound: Doxorubicin	Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HCT-15	GI₅₀	6.46 μM Compound: Doxorubicin	Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HCT-15	GI₅₀	7.92 μM Compound: Doxorubicin	Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay	[PMID: 19394218]
HCT-15	IC₅₀	81 nM Compound: doxorubicin	Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay	[PMID: 19655762]
HCT-29	IC₅₀	2.5 μM Compound: Adriamycin	Cytotoxicity against human HCT29 cells after 4 days by MTT assay Cytotoxicity against human HCT29 cells after 4 days by MTT assay	[PMID: 21704436]
HCT-8	IC₅₀	0.01 μg/mL Compound: Dox	Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay	10.1007/s00044-011-9894-8
HCT-8	IC₅₀	0.02 μM Compound: Dox	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 25147145]
HCT-8	IC₅₀	0.02 μM Compound: D	Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 22000949]
HCT-8	IC₅₀	0.02 μM Compound: doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 21381705]
HCT-8	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 20971532]
HCT-8	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19406535]
HCT-8	IC₅₀	0.03 μM Compound: Dox	Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31306817]
HCT-8	IC₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 3 days by MTT assay Cytotoxicity against human HCT8 cells after 3 days by MTT assay	[PMID: 19159272]
HCT-8	IC₅₀	0.04 μg/mL Compound: Dox	Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay	10.1007/s00044-012-0236-2
HCT-8	IC₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19084293]
HCT-8	IC₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 18586355]
HCT-8	IC₅₀	0.04 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 17827021]
HCT-8	IC₅₀	0.04 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 15787450]
HCT-8	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 27363939]
HCT-8	IC₅₀	0.06 μg/mL Compound: Doxo	Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay	[PMID: 21334795]
HCT-8	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 21115213]
HCT-8	IC₅₀	0.06 μM Compound: DOXO	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19947600]
HCT-8	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay	[PMID: 19780590]
HCT-8	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells by colorimetric method Cytotoxicity against human HCT8 cells by colorimetric method	[PMID: 24387625]
HCT-8	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 22250891]
HCT-8	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
HCT-8	IC₅₀	0.19 μM Compound: DOXO	Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
HCT-8	IC₅₀	0.42 μM Compound: Adriamycin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 22070654]
HCT-8	IC₅₀	0.8 μM Compound: adriamycin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 17190442]
HCT-8	IC₅₀	1.17 μM Compound: DOX	Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
HCT-8	IC₅₀	1.5 μM Compound: doxorubicine	Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay	[PMID: 19788290]
HCT-8	IC₅₀	19.6 μM Compound: Dox	Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method	[PMID: 25375258]
HCT-8	IC₅₀	2.4 μM Compound: Dox	Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method	[PMID: 25375258]
HCT-8	IC₅₀	3.4 μM Compound: DOX	Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method	[PMID: 25061803]
HCT-8	IC₅₀	7.2 μM Compound: Doxorubicin	Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay	[PMID: 30660827]
HEK293	IC₅₀	> 100 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells by MTT assay Cytotoxicity against HEK293 cells by MTT assay	[PMID: 24287557]
HEK293	IC₅₀	> 200 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
HEK293	IC₅₀	> 200 μM Compound: Doxorubicin	In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay	[PMID: 24742385]
HEK293	IC₅₀	0.01 μM Compound: Adriamycin	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 21721528]
HEK293	IC₅₀	0.018 μM Compound: DOX	Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay	[PMID: 31431364]
HEK293	IC₅₀	0.02 μM Compound: DOX	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
HEK293	IC₅₀	0.04 μM Compound: ADM	Cytotoxic activity against human HEK293 cells by SRB method Cytotoxic activity against human HEK293 cells by SRB method	[PMID: 25611519]
HEK293	IC₅₀	0.064 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells after 24 hrs by SRB method Cytotoxicity against HEK293 cells after 24 hrs by SRB method	[PMID: 18429610]
HEK293	IC₅₀	0.106 μM Compound: Dox	Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method	[PMID: 34236840]
HEK293	IC₅₀	0.36 μM Compound: DX	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 29681486]
HEK293	IC₅₀	0.42 μM Compound: Adriamycin	Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay	[PMID: 21721528]
HEK293	IC₅₀	0.46 μM Compound: DX	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay	[PMID: 30108984]
HEK293	IC₅₀	0.46 μM Compound: Dox	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay	[PMID: 28372935]
HEK293	IC₅₀	0.46 μM Compound: DX	Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay	[PMID: 26690914]
HEK293	IC₅₀	0.46 μM Compound: DX	Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay	[PMID: 26052884]
HEK293	IC₅₀	0.46 μM Compound: doxorubicin	Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay	[PMID: 25868743]
HEK293	IC₅₀	0.69 μM Compound: Doxorubicin	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 25300819]
HEK293	IC₅₀	0.7 μM Compound: Doxorubicin	Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay	10.1039/C1MD00234A
HEK293	GI₅₀	0.8 μM Compound: Dox	Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HEK293	IC₅₀	0.9 μM Compound: doxorubicin	Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay	[PMID: 21058726]
HEK293	IC₅₀	1 μg/mL Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35526504]
HEK293	IC₅₀	1 μM Compound: ADR	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 22819942]
HEK293	IC₅₀	1.006 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells after 24 hrs by MTT assay Cytotoxicity against HEK293 cells after 24 hrs by MTT assay	10.1007/s00044-013-0784-0
HEK293	IC₅₀	1.06 μM Compound: Adriamycin	Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay	[PMID: 24582982]
HEK293	IC₅₀	1.2 μM Compound: DOX	Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 30429098]
HEK293	IC₅₀	1.34 μM Compound: Adriamycin	Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
HEK293	IC₅₀	1.65 μM Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34124677]
HEK293	IC₅₀	10 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
HEK293	IC₅₀	11.34 mM Compound: DOX	Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 31648875]
HEK293	IC₅₀	142.8 μM Compound: 12	Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay	[PMID: 29852328]
HEK293	IC₅₀	148.4 μM Compound: 21	Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay	[PMID: 29289880]
HEK293	IC₅₀	16.7 μg/mL Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35526504]
HEK293	IC₅₀	160 μM Compound: Doxorubicin	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
HEK293	IC₅₀	240 μM Compound: Doxorubicin	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	3.07 μM Compound: Adriamycin	Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay	[PMID: 24013413]
HEK293	IC₅₀	3.13 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27816268]
HEK293	IC₅₀	3.9 μM Compound: Doxorubicin	Growth inhibition of HEK293 cells after 48 hrs by MTT assay Growth inhibition of HEK293 cells after 48 hrs by MTT assay	[PMID: 30072225]
HEK293	IC₅₀	41 μM Compound: Doxorubicin	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	44.4 μM Compound: DOX	Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay	[PMID: 27108400]
HEK293	IC₅₀	455 nM Compound: DX	Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test	[PMID: 24996140]
HEK293	IC₅₀	5.68 μM Compound: DOX	Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 31671309]
HEK293	IC₅₀	5.68 μM Compound: DOX	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 30576904]
HEK293	IC₅₀	6.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35526504]
HEK293	IC₅₀	6.1 μM Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay	[PMID: 32165076]
HEK293	IC₅₀	7.2 μM Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
HEK293	IC₅₀	7.41 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells after 48 hrs by MTT assay Cytotoxicity against HEK293 cells after 48 hrs by MTT assay	[PMID: 24607876]
HEK-293T	IC₅₀	0.75 μM Compound: DOX	Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HEK-293T	IC₅₀	0.75 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS	[PMID: 26298501]
HEK-293T	IC₅₀	0.84 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS	[PMID: 26298501]
HEK-293T	IC₅₀	1.051 μM Compound: Dox	Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay	[PMID: 31542715]
HEK-293T	IC₅₀	1.13 μM Compound: Doxorubicin	Cytotoxicity against HEK293T cells after 48 hrs by MTT assay Cytotoxicity against HEK293T cells after 48 hrs by MTT assay	[PMID: 30170925]
HEK-293T	CC₅₀	1.13 μM Compound: Doxorubicin	Cytotoxicity against HEK293T cells after 48 hrs by MTT assay Cytotoxicity against HEK293T cells after 48 hrs by MTT assay	[PMID: 30103191]
HEK-293T	IC₅₀	1.2 μM Compound: Dox	Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 27055942]
HEK-293T	IC₅₀	3.1 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay	[PMID: 27173802]
HEK-293T	IC₅₀	3.59 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay	[PMID: 29573910]
HEK-293T	IC₅₀	3.77 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35367708]
HEK-293T	IC₅₀	3.77 μM Compound: Doxorubicin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31404864]
HEL	IC₅₀	0.42 μM Compound: Doxorubicin	Antiproliferative activity against HEL cells after 72 hrs by MTT assay Antiproliferative activity against HEL cells after 72 hrs by MTT assay	[PMID: 30500683]
HEL	IC₅₀	2.13 μM Compound: Doxorubicin	Cytotoxicity against HEL cells after 48 hrs by MTT assay Cytotoxicity against HEL cells after 48 hrs by MTT assay	[PMID: 28390228]
HeLa	GI₅₀	< 0.01 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 25827522]
HeLa	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human HeLa cells by SRB assay Cytotoxicity against human HeLa cells by SRB assay	10.1007/s00044-013-0855-2
HeLa	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay	10.1007/s00044-011-9884-x
HeLa	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 23079527]
HeLa	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 21996519]
HeLa	IC₅₀	> 1 μM Compound: Doxorubicin	Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa	IC₅₀	0.008 mM Compound: DOX	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 22520152]
HeLa	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay	[PMID: 25059501]
HeLa	IC₅₀	0.016 μM Compound: DOX	Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay	10.1007/s00044-012-0051-9
HeLa	GI₅₀	0.023 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells by SRB assay Antiproliferative activity against human HeLa cells by SRB assay	[PMID: 31546197]
HeLa	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay	[PMID: 27080175]
HeLa	GI₅₀	0.031 μM Compound: Doxorubicin	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 26067381]
HeLa	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20207049]
HeLa	IC₅₀	0.04 μM Compound: DOX	Antitumor activity against human HeLa cells after 72 hrs by MTT assay Antitumor activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 17935309]
HeLa	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19278239]
HeLa	GI₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27889456]
HeLa	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 28257197]
HeLa	IC₅₀	0.051 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
HeLa	IC₅₀	0.053 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay	10.1007/s00044-010-9340-3
HeLa	IC₅₀	0.06 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 22555152]
HeLa	IC₅₀	0.065 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HeLa	IC₅₀	0.065 μM Compound: DOX	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25259516]
HeLa	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
HeLa	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33340938]
HeLa	IC₅₀	0.07 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
HeLa	IC₅₀	0.07 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
HeLa	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28135634]
HeLa	IC₅₀	0.07 μM Compound: Dox	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
HeLa	IC₅₀	0.07 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
HeLa	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24021462]
HeLa	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20359789]
HeLa	IC₅₀	0.07 μM Compound: DOX	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18783950]
HeLa	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay	[PMID: 19053767]
HeLa	IC₅₀	0.07 μM Compound: doxo	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 16913700]
HeLa	GI₅₀	0.073 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27209232]
HeLa	GI₅₀	0.073 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay	[PMID: 25462234]
HeLa	GI₅₀	0.073 μM Compound: Doxorubicin	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 25264072]
HeLa	GI₅₀	0.083 μM Compound: Doxorubicin	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 27964883]
HeLa	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36693198]
HeLa	GI₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 26994690]
HeLa	GI₅₀	0.093 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 30360625]
HeLa	ED₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 16252910]
HeLa	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28398051]
HeLa	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method	[PMID: 25932671]
HeLa	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 26947606]
HeLa	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30389295]
HeLa	IC₅₀	0.13 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21496972]
HeLa	ED₅₀	0.14 μg/mL Compound: doxorubicin	Cytotoxicity against human HeLa cells by methylene blue staining method Cytotoxicity against human HeLa cells by methylene blue staining method	[PMID: 15921421]
HeLa	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 31820973]
HeLa	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by XTT assay Cytotoxicity against human HeLa cells after 24 hrs by XTT assay	[PMID: 27227682]
HeLa	IC₅₀	0.154 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25462279]
HeLa	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18692939]
HeLa	IC₅₀	0.163 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21158422]
HeLa	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 22414612]
HeLa	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by XTT assay Cytotoxicity against human HeLa cells after 72 hrs by XTT assay	[PMID: 19647439]
HeLa	IC₅₀	0.2 mM Compound: Dox	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29459273]
HeLa	IC₅₀	0.2 μM Compound: Doxo	Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
HeLa	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
HeLa	IC₅₀	0.2 μM Compound: 2	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 33974416]
HeLa	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30659997]
HeLa	IC₅₀	0.2 μM Compound: Dox	Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay	[PMID: 30268824]
HeLa	IC₅₀	0.2 μM Compound: 5	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29137865]
HeLa	IC₅₀	0.2 μM Compound: 1; Dox	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26633734]
HeLa	IC₅₀	0.2 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
HeLa	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19394829]
HeLa	IC₅₀	0.21 μM Compound: ADM	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
HeLa	IC₅₀	0.21 μM Compound: ADM	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25529742]
HeLa	IC₅₀	0.21 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs MTT assay Antiproliferative activity against human HeLa cells after 72 hrs MTT assay	[PMID: 25247772]
HeLa	ED₅₀	0.22 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 15104488]
HeLa	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay	[PMID: 25163667]
HeLa	IC₅₀	0.221 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
HeLa	IC₅₀	0.23 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21641694]
HeLa	IC₅₀	0.24 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21708464]
HeLa	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay	[PMID: 32040324]
HeLa	IC₅₀	0.256 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay	[PMID: 33276991]
HeLa	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26972921]
HeLa	GI₅₀	0.3 μM Compound: Dox	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HeLa	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 44 hrs by SRB assay Cytotoxicity against human HeLa cells after 44 hrs by SRB assay	10.1007/s00044-013-0788-9
HeLa	IC₅₀	0.32 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28358196]
HeLa	GI₅₀	0.33 μM Compound: Doxorubicin	Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay	10.1007/s00044-012-0232-6
HeLa	IC₅₀	0.33 μM Compound: Doxorubicin	Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HeLa	IC₅₀	0.33 μM Compound: DOX	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 20171108]
HeLa	IC₅₀	0.337 μM Compound: Dox	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25998504]
HeLa	IC₅₀	0.34 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
HeLa	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
HeLa	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HeLa	IC₅₀	0.36 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24487188]
HeLa	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25453799]
HeLa	IC₅₀	0.37 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay	[PMID: 28579122]
HeLa	IC₅₀	0.4 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay	[PMID: 31679979]
HeLa	IC₅₀	0.41 μM Compound: adriamycin	Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay	[PMID: 19072548]
HeLa	IC₅₀	0.429 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay	[PMID: 36652792]
HeLa	IC₅₀	0.43 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS	[PMID: 26298501]
HeLa	IC₅₀	0.45 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25172420]
HeLa	IC₅₀	0.45 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 23911578]
HeLa	IC₅₀	0.45 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS	[PMID: 26298501]
HeLa	IC₅₀	0.451 μM Compound: DOXO	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29685681]
HeLa	IC₅₀	0.451 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 24113366]
HeLa	IC₅₀	0.451 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 23764302]
HeLa	IC₅₀	0.47 μM Compound: adriamycin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26295905]
HeLa	IC₅₀	0.47 μM Compound: ADM	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 25089733]
HeLa	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
HeLa	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 32324401]
HeLa	IC₅₀	0.5 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTS assay Cytotoxicity against human HeLa cells after 72 hrs by MTS assay	[PMID: 25490132]
HeLa	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29702447]
HeLa	IC₅₀	0.5 μM Compound: ADM	Cytotoxic activity against human HeLa cells by MTT method Cytotoxic activity against human HeLa cells by MTT method	[PMID: 25611519]
HeLa	IC₅₀	0.5 μM Compound: ADM	Cytotoxicity against human HeLa cells by SRB method Cytotoxicity against human HeLa cells by SRB method	[PMID: 29144133]
HeLa	IC₅₀	0.509 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay	[PMID: 23932340]
HeLa	IC₅₀	0.509 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 24287557]
HeLa	IC₅₀	0.51 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26381063]
HeLa	IC₅₀	0.51 μM Compound: Doxorubicin	In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay	[PMID: 24742385]
HeLa	IC₅₀	0.52 μM Compound: DOX	Cytotoxicity against human HeLa cells measured after 2 days by MTT assay Cytotoxicity against human HeLa cells measured after 2 days by MTT assay	[PMID: 26334499]
HeLa	IC₅₀	0.54 μg/mL Compound: Doxorubicin	Anticancer activity against human HeLa cells by MTT assay Anticancer activity against human HeLa cells by MTT assay	[PMID: 31404864]
HeLa	IC₅₀	0.55 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HeLa	IC₅₀	0.59 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 34978808]
HeLa	IC₅₀	0.6 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30679134]
HeLa	IC₅₀	0.6 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26386603]
HeLa	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 22749279]
HeLa	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay	[PMID: 27187861]
HeLa	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25241926]
HeLa	IC₅₀	0.606 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28406643]
HeLa	IC₅₀	0.62 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19689125]
HeLa	IC₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30170925]
HeLa	CC₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30103191]
HeLa	IC₅₀	0.68 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18440233]
HeLa	IC₅₀	0.69 μM Compound: Doxorubicin	Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31324563]
HeLa	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy	[PMID: 28615134]
HeLa	GI₅₀	0.7 μM Compound: Dox	Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
HeLa	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25172418]
HeLa	IC₅₀	0.71 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay	10.1007/s00044-012-0370-x
HeLa	IC₅₀	0.71 μM Compound: Doxorubicine	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22014995]
HeLa	IC₅₀	0.73 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19819703]
HeLa	GI₅₀	0.76 μM Compound: Dox	Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HeLa	IC₅₀	0.78 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27060757]
HeLa	IC₅₀	0.8 μg/mL Compound: Adriamycin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 17918910]
HeLa	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 30654238]
HeLa	IC₅₀	0.8 μM Compound: Dox	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
HeLa	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 31404864]
HeLa	IC₅₀	0.834 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
HeLa	IC₅₀	0.85 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HeLa	IC₅₀	0.88 μM Compound: adriamycin	Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay	[PMID: 25936262]
HeLa	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25462233]
HeLa	IC₅₀	0.93 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HeLa	IC₅₀	0.97 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 24182355]
HeLa	IC₅₀	1 x 10^-2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay	[PMID: 23470139]
HeLa	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay	[PMID: 25481396]
HeLa	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
HeLa	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19632833]
HeLa	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells by neutral red method Cytotoxicity against human HeLa cells by neutral red method	[PMID: 26291474]
HeLa	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 21601964]
HeLa	IC₅₀	1.009 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by SRB method Cytotoxicity against human HeLa cells after 24 hrs by SRB method	[PMID: 18429610]
HeLa	IC₅₀	1.02 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by CCK8 assay Cytotoxicity against human HeLa cells by CCK8 assay	[PMID: 29452840]
HeLa	IC₅₀	1.07 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HeLa	IC₅₀	1.089 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
HeLa	IC₅₀	1.107 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 32707525]
HeLa	IC₅₀	1.1073 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 31404864]
HeLa	IC₅₀	1.12 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	10.1039/C3MD00013C
HeLa	IC₅₀	1.12 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 22182926]
HeLa	IC₅₀	1.17 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay	10.1039/C2MD20327H
HeLa	IC₅₀	1.17 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30108986]
HeLa	IC₅₀	1.17 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 25737400]
HeLa	IC₅₀	1.17 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25619894]
HeLa	IC₅₀	1.17 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24148837]
HeLa	IC₅₀	1.17 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 1 hr by SRB assay Cytotoxicity against human HeLa cells after 1 hr by SRB assay	[PMID: 22770744]
HeLa	IC₅₀	1.2 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 33421712]
HeLa	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26398312]
HeLa	IC₅₀	1.2 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28886509]
HeLa	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 33766771]
HeLa	IC₅₀	1.2 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
HeLa	IC₅₀	1.21 μM Compound: Dox	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
HeLa	IC₅₀	1.258 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26301558]
HeLa	IC₅₀	1.28 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	10.1039/C4MD00566J
HeLa	IC₅₀	1.3 μM Compound: Doxorubicin	Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 25966052]
HeLa	IC₅₀	1.31 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24582982]
HeLa	IC₅₀	1.43 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by SRB method Cytotoxicity against human HeLa cells after 48 hrs by SRB method	[PMID: 25933593]
HeLa	IC₅₀	1.44 μM Compound: doxo	Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay	[PMID: 30763817]
HeLa	IC₅₀	1.45 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 22318164]
HeLa	IC₅₀	1.5 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24941129]
HeLa	IC₅₀	1.5 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22044164]
HeLa	IC₅₀	1.51 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26330077]
HeLa	IC₅₀	1.59 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26948541]
HeLa	IC₅₀	1.6 x 10^-2 μM Compound: adriamycin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19285863]
HeLa	IC₅₀	1.64 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21534590]
HeLa	IC₅₀	1.68 μM Compound: Dox	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26494582]
HeLa	IC₅₀	1.69 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30500683]
HeLa	IC₅₀	1.73 μM Compound: Doxo	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29129513]
HeLa	IC₅₀	1.78 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26708114]
HeLa	IC₅₀	1.8 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells by MTT assay Anticancer activity against human HeLa cells by MTT assay	[PMID: 33421712]
HeLa	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay	[PMID: 33421712]
HeLa	IC₅₀	1.81 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay	[PMID: 29409753]
HeLa	IC₅₀	1.82 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29172084]
HeLa	IC₅₀	1.862 μM Compound: Doxorubicin	Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 27744185]
HeLa	IC₅₀	1.91 μM Compound: II	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29289881]
HeLa	IC₅₀	1.94 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
HeLa	IC₅₀	1.96 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]
HeLa	IC₅₀	1.995 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29501940]
HeLa	GI₅₀	10.7 μM Compound: DOX	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 28433679]
HeLa	IC₅₀	10.78 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay	[PMID: 26022842]
HeLa	IC₅₀	11 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 11473441]
HeLa	IC₅₀	11.5 μM Compound: Doxo	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27597408]
HeLa	IC₅₀	13 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35526504]
HeLa	IC₅₀	14 μM Compound: DOX	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 31015907]
HeLa	CC₅₀	2 μg/mL Compound: doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining	[PMID: 20153202]
HeLa	IC₅₀	2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31938458]
HeLa	IC₅₀	2 μM Compound: adriamycin	Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay	[PMID: 17993275]
HeLa	IC₅₀	2.05 μM Compound: Doxorubicin	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 28147307]
HeLa	IC₅₀	2.089 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28462842]
HeLa	IC₅₀	2.09 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
HeLa	IC₅₀	2.1 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
HeLa	IC₅₀	2.2 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 23218718]
HeLa	IC₅₀	2.23 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
HeLa	IC₅₀	2.29 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25615796]
HeLa	IC₅₀	2.3 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay	[PMID: 28291684]
HeLa	IC₅₀	2.45 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay	[PMID: 35344904]
HeLa	EC₅₀	2.5 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay	10.1007/s00044-012-0294-5
HeLa	IC₅₀	2.57 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27015609]
HeLa	IC₅₀	2.63 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26264845]
HeLa	IC₅₀	2.684 μg/mL Compound: ADM	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25862199]
HeLa	IC₅₀	2.78 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay	[PMID: 32631524]
HeLa	IC₅₀	2.9 x 10^-1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by XTT assay Cytotoxicity against human HeLa cells after 72 hrs by XTT assay	[PMID: 20619940]
HeLa	IC₅₀	20.93 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 22818039]
HeLa	IC₅₀	21.9 μM Compound: DXR	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
HeLa	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay	[PMID: 33461146]
HeLa	IC₅₀	3.24 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 23835482]
HeLa	IC₅₀	3.24 μM Compound: Doxorubicin	Cytotoxicity against human HeLa after 24 hrs by MTT assay Cytotoxicity against human HeLa after 24 hrs by MTT assay	[PMID: 20056520]
HeLa	IC₅₀	3.24 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 19128861]
HeLa	IC₅₀	3.24 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay	[PMID: 24856067]
HeLa	IC₅₀	3.3 μM Compound: adriamycin	Cytotoxicity against human HeLa cells after 4 days by MTT assay Cytotoxicity against human HeLa cells after 4 days by MTT assay	[PMID: 17194586]
HeLa	IC₅₀	3.3 μM Compound: DOX	Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 30846253]
HeLa	IC₅₀	3.33 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay	[PMID: 36652792]
HeLa	IC₅₀	3.55 μM Compound: DOX	Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay	[PMID: 30746067]
HeLa	IC₅₀	3.57 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25594739]
HeLa	IC₅₀	3.64 μg/mL Compound: DOX	Antitumor activity against human HeLa cells after 48 hrs by MTT assay Antitumor activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20599299]
HeLa	IC₅₀	3.7 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 4 days by MTT assay Cytotoxicity against human HeLa cells after 4 days by MTT assay	[PMID: 21704436]
HeLa	IC₅₀	3.9 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
HeLa	IC₅₀	3.92 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26542964]
HeLa	IC₅₀	3.97 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31404864]
HeLa	IC₅₀	3.99 μM Compound: AMD	Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 27639364]
HeLa	IC₅₀	30.21 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells after 48 hrs by SRB assay Anticancer activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 24077528]
HeLa	IC₅₀	37 nM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay	[PMID: 20180542]
HeLa	IC₅₀	4 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay	[PMID: 27618204]
HeLa	IC₅₀	4.1 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 23748152]
HeLa	IC₅₀	4.16 nM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
HeLa	IC₅₀	4.61 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35367708]
HeLa	IC₅₀	4.8 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28254167]
HeLa	IC₅₀	5 mM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 23685942]
HeLa	IC₅₀	5 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27173802]
HeLa	IC₅₀	5.17 μM Compound: Doxorubicin	Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30138804]
HeLa	IC₅₀	5.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 27769619]
HeLa	IC₅₀	5.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 26252628]
HeLa	IC₅₀	5.23 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29573910]
HeLa	IC₅₀	5.3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 22304344]
HeLa	IC₅₀	5.57 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
HeLa	IC₅₀	5.57 μM Compound: DOX	Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32085964]
HeLa	IC₅₀	5.57 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa after 24 hrs by MTT assay Antiproliferative activity against human HeLa after 24 hrs by MTT assay	[PMID: 30826188]
HeLa	IC₅₀	5.57 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HeLa	IC₅₀	5.57 μM Compound: Dox	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32527460]
HeLa	IC₅₀	5.57 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29702448]
HeLa	IC₅₀	5.57 μM Compound: DOX	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 30216848]
HeLa	IC₅₀	5.7 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay	[PMID: 34223162]
HeLa	IC₅₀	55 nM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay	[PMID: 20180542]
HeLa	IC₅₀	57.8 μM Compound: DOX	Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35859879]
HeLa	IC₅₀	6 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25453802]
HeLa	IC₅₀	6.3 μM Compound: ADR	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	10.1039/C2MD20270K
HeLa	IC₅₀	6.3 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30660827]
HeLa	GI₅₀	6.7 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 29316526]
HeLa	IC₅₀	6.94 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24607876]
HeLa	IC₅₀	7.01 μM Compound: Doxo	Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay	[PMID: 31104996]
HeLa	IC₅₀	7.04 μM Compound: DOX	Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay	[PMID: 25064350]
HeLa	IC₅₀	7.18 μM Compound: Dox	Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay	[PMID: 28129977]
HeLa	IC₅₀	7.2 μM Compound: DX	Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay	10.1039/C5MD00513B
HeLa	IC₅₀	7.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35526504]
HeLa	GI₅₀	7.51 μM Compound: Doxo	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26513642]
HeLa	IC₅₀	7.71 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 23994327]
HeLa	IC₅₀	7.9 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 31589431]
HeLa	IC₅₀	71 nM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 28600080]
HeLa	IC₅₀	780 nM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30172625]
HeLa	IC₅₀	8.1 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis	[PMID: 34438126]
HeLa	IC₅₀	8.3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis	[PMID: 28756265]
HeLa	IC₅₀	8.66 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30398868]
HeLa	IC₅₀	8.72 μg/mL Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 19932530]
HeLa	IC₅₀	8.87 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 35964425]
HeLa	IC₅₀	8.96 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by WST-8 assay Cytotoxicity against human HeLa cells by WST-8 assay	[PMID: 29295796]
HeLa	IC₅₀	9.03 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 26873414]
HeLa	IC₅₀	90 nM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa S3	IC₅₀	< 0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HeLaS3 cells by MTT assay Antiproliferative activity against human HeLaS3 cells by MTT assay	[PMID: 29072457]
HeLa S3	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay	[PMID: 26963142]
HeLa S3	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HeLaS3 cells by MTT assay Cytotoxicity against human HeLaS3 cells by MTT assay	[PMID: 30719909]
HeLa S3	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay	[PMID: 30978023]
HeLa S3	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32627543]
Hep 3B2	IC₅₀	0.14 μM Compound: Doxorubucin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 20718475]
Hep 3B2	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 18973388]
Hep 3B2	IC₅₀	0.27 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 18590313]
Hep 3B2	IC₅₀	0.29 μM Compound: DOX	Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay	[PMID: 23290052]
Hep 3B2	IC₅₀	0.31 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 15387653]
Hep 3B2	IC₅₀	0.41 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 19691312]
Hep 3B2	IC₅₀	0.42 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 21106454]
Hep 3B2	IC₅₀	0.45 μg/mL Compound: doxo	Cytotoxicity against human Hep3B cells by MTT method Cytotoxicity against human Hep3B cells by MTT method	[PMID: 17417907]
Hep 3B2	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 18547115]
Hep 3B2	IC₅₀	0.59 μM Compound: doxorubicin	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 18419154]
Hep 3B2	IC₅₀	0.6 μM Compound: Doxo	Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay	[PMID: 20334960]
Hep 3B2	IC₅₀	0.62 μM Compound: doxorubicin	Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method	[PMID: 17622129]
Hep 3B2	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 21425785]
Hep 3B2	IC₅₀	1.02 μM Compound: Doxorubicin	Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34838335]
Hep 3B2	IC₅₀	1.03 μM Compound: Doxo	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 21800859]
Hep 3B2	IC₅₀	1.15 μM Compound: Dox	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 28262527]
Hep 3B2	IC₅₀	1.31 μg/mL Compound: doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 22413887]
Hep 3B2	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
Hep 3B2	IC₅₀	13.25 μM Compound: Dox	Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay	[PMID: 24929289]
Hep 3B2	IC₅₀	16 μM Compound: DOX	Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
Hep 3B2	IC₅₀	2.4 μM Compound: Doxorubicin	Growth inhibition of human Hep3B cells by MTT assay Growth inhibition of human Hep3B cells by MTT assay	[PMID: 28916158]
Hep 3B2	IC₅₀	4.5 μM Compound: Dox	Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay	[PMID: 28865276]
Hep 3B2	EC₅₀	5.6 μM Compound: doxorubicin	Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay	[PMID: 20455578]
HEp-2	IC₅₀	0.04 μM Compound: DOX	Antitumor activity against human Hep2 cells after 72 hrs by MTT assay Antitumor activity against human Hep2 cells after 72 hrs by MTT assay	[PMID: 17935309]
HEp-2	IC₅₀	0.04 μM Compound: doxo	Antiproliferative activity against human Hep2 cell line by MTT assay Antiproliferative activity against human Hep2 cell line by MTT assay	[PMID: 16913700]
HEp-2	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep2 cells after 24 hrs Cytotoxicity against human Hep2 cells after 24 hrs	[PMID: 20207452]
HEp-2	IC₅₀	0.42 μM Compound: doxorubicin	Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay	[PMID: 18281125]
HEp-2	IC₅₀	0.42 μM Compound: doxorubicin	Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay	[PMID: 17400463]
HEp-2	IC₅₀	0.51 μM Compound: Doxorubicin	Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay	[PMID: 29885574]
HEp-2	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 29329071]
HEp-2	IC₅₀	1.29 μM Compound: Doxorubicin	Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay	[PMID: 27116711]
HEp-2	IC₅₀	1.3 μM Compound: Doxorubicin	Growth inhibition of human Hep2 cells after 72 hrs by MTT assay Growth inhibition of human Hep2 cells after 72 hrs by MTT assay	[PMID: 28189083]
HEp-2	IC₅₀	1.5 μM Compound: Adriamycin	Cytotoxicity against human Hep2 cells by neutral red method Cytotoxicity against human Hep2 cells by neutral red method	[PMID: 26291474]
HEp-2	IC₅₀	1.78 μM Compound: DOX	Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
HEp-2	IC₅₀	6.32 μM Compound: Doxorubicin	Antiproliferative activity against human Hep2 after 24 hrs by MTT assay Antiproliferative activity against human Hep2 after 24 hrs by MTT assay	[PMID: 30826188]
HEp-2	IC₅₀	8.54 μM Compound: DOX	Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
HEp-2	IC₅₀	8.7 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay	10.1007/s00044-012-0370-x
HEp-2	IC₅₀	8.7 μM Compound: Doxorubicine	Cytotoxicity against human Hep2 cells by MTT assay Cytotoxicity against human Hep2 cells by MTT assay	[PMID: 22014995]
HepG2	IC₅₀	< 2.94 μM Compound: Doxorubicin	Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay	[PMID: 20810194]
HepG2	EC₅₀	> 10 μM Compound: doxorubicin	Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay	[PMID: 20455578]
HepG2	IC₅₀	> 40 μg/mL Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 12608856]
HepG2	IC₅₀	> 50 μM Compound: DOX	Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay	[PMID: 27889629]
HepG2	IC₅₀	> 75 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
HepG2	IC₅₀	0.007 ug Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay	[PMID: 27393950]
HepG2	IC₅₀	0.009 mM Compound: DOX	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 22520152]
HepG2	GI₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 27889456]
HepG2	IC₅₀	0.01 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 30826510]
HepG2	IC₅₀	0.017 g/L Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay	10.1007/s00044-010-9433-z
HepG2	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27886545]
HepG2	CC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 25282267]
HepG2	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay	[PMID: 31403289]
HepG2	GI₅₀	0.04 μM Compound: Dox	Growth inhibition of human HepG2 cells by MTT assay Growth inhibition of human HepG2 cells by MTT assay	[PMID: 31330449]
HepG2	IC₅₀	0.05 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22555152]
HepG2	CC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32088496]
HepG2	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34782182]
HepG2	IC₅₀	0.06 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells by SRB method Cytotoxicity against human HepG2 cells by SRB method	[PMID: 18181575]
HepG2	IC₅₀	0.069 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31999451]
HepG2	IC₅₀	0.08 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23802716]
HepG2	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay	[PMID: 28398051]
HepG2	IC₅₀	0.1 μM Compound: doxorubicin	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 18313307]
HepG2	IC₅₀	0.16 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 19691312]
HepG2	IC₅₀	0.16 μM Compound: ADM; DOX	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
HepG2	IC₅₀	0.17 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 18590313]
HepG2	IC₅₀	0.17 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 6 days by MTT method Cytotoxicity against human HepG2 cells after 6 days by MTT method	[PMID: 16309317]
HepG2	IC₅₀	0.18 μg/mL Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 16252914]
HepG2	IC₅₀	0.18 μg/mL Compound: doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 22413887]
HepG2	IC₅₀	0.19 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 15387653]
HepG2	IC₅₀	0.19 μM Compound: DOX	Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 23290052]
HepG2	GI₅₀	0.19 μM Compound: DOX	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 30336023]
HepG2	GI₅₀	0.19 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
HepG2	IC₅₀	0.19 μM Compound: DOX	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21496972]
HepG2	IC₅₀	0.19 μM Compound: Doxorubucin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 20718475]
HepG2	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 18973388]
HepG2	IC₅₀	0.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep G2 cells by MTT colorimetric method Cytotoxicity against human Hep G2 cells by MTT colorimetric method	[PMID: 17125220]
HepG2	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28277681]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34364164]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32795774]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32652409]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32292551]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30655943]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30092366]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29885575]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27654395]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 27155463]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 25846065]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25791675]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 25559208]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 24946216]
HepG2	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24650715]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 24080103]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22889559]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22608675]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21852132]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21741131]
HepG2	IC₅₀	0.2 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19926173]
HepG2	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19482476]
HepG2	IC₅₀	0.2 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 17981462]
HepG2	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
HepG2	IC₅₀	0.21 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31836446]
HepG2	IC₅₀	0.22 μg/mL Compound: Doxorubicin	Cytotoxic activity against human HepG2 cells by MTT assay Cytotoxic activity against human HepG2 cells by MTT assay	[PMID: 28366267]
HepG2	IC₅₀	0.23 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining	10.1007/s00044-012-0025-y
HepG2	IC₅₀	0.23 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay	10.1007/s00044-011-9903-y
HepG2	IC₅₀	0.23 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21106454]
HepG2	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay	[PMID: 28038943]
HepG2	GI₅₀	0.25 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26561866]
HepG2	IC₅₀	0.26 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 21741833]
HepG2	IC₅₀	0.29 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21174408]
HepG2	IC₅₀	0.3 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 16724859]
HepG2	IC₅₀	0.3 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 24050254]
HepG2	IC₅₀	0.3 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HepG2	IC₅₀	0.3 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19632833]
HepG2	EC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 26320088]
HepG2	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 29975532]
HepG2	IC₅₀	0.36 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25314138]
HepG2	IC₅₀	0.37 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 4 days by MTT assay Cytotoxicity against human HepG2 cells after 4 days by MTT assay	[PMID: 19824618]
HepG2	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20846862]
HepG2	IC₅₀	0.38 μM Compound: Doxorubicin	Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 27080187]
HepG2	IC₅₀	0.39 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 36089748]
HepG2	IC₅₀	0.392 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay	[PMID: 28797771]
HepG2	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
HepG2	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay	[PMID: 26469557]
HepG2	IC₅₀	0.4 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay	[PMID: 25490132]
HepG2	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 25747499]
HepG2	IC₅₀	0.41 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HepG2	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HepG2	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay	10.1007/s00044-012-0402-6
HepG2	IC₅₀	0.425 μM Compound: DOX	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HepG2	IC₅₀	0.45 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells by MTT assay Anticancer activity against human HepG2 cells by MTT assay	[PMID: 31404864]
HepG2	IC₅₀	0.46 μg/mL Compound: doxo	Cytotoxicity against human HepG2 cells by MTT method Cytotoxicity against human HepG2 cells by MTT method	[PMID: 17417907]
HepG2	IC₅₀	0.467 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay	[PMID: 35694689]
HepG2	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 24852278]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay	[PMID: 31926469]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 25554367]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 31148449]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells after 48 hrs by MTT assay Anticancer activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21641694]
HepG2	IC₅₀	0.5 μM Compound: Doxo	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 20334960]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	10.1039/C3MD00166K
HepG2	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 24182355]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21425785]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 29035560]
HepG2	IC₅₀	0.5 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method	[PMID: 17622129]
HepG2	IC₅₀	0.52 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30389295]
HepG2	IC₅₀	0.54 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
HepG2	IC₅₀	0.54 μM Compound: Dox	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 28262527]
HepG2	IC₅₀	0.55 μM Compound: DX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 29681486]
HepG2	IC₅₀	0.55 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31704206]
HepG2	IC₅₀	0.57 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26397393]
HepG2	IC₅₀	0.57 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25019480]
HepG2	IC₅₀	0.58 μM Compound: DOX	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26386603]
HepG2	IC₅₀	0.59 μg/mL Compound: Dox	Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay	[PMID: 20399544]
HepG2	IC₅₀	0.59 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23806110]
HepG2	IC₅₀	0.6 μg/mL Compound: Doxorubicine	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 24177357]
HepG2	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 24300737]
HepG2	IC₅₀	0.62 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32438251]
HepG2	IC₅₀	0.62 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay	[PMID: 29885574]
HepG2	IC₅₀	0.63 μM Compound: Doxo	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 21800859]
HepG2	IC₅₀	0.64 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
HepG2	IC₅₀	0.64 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 18419154]
HepG2	IC₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34838335]
HepG2	EC₅₀	0.67 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35567964]
HepG2	IC₅₀	0.67 μM Compound: DOX	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
HepG2	IC₅₀	0.68 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
HepG2	IC₅₀	0.68 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay	[PMID: 27422336]
HepG2	IC₅₀	0.69 μM Compound: DOX	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 33276990]
HepG2	IC₅₀	0.69 μM Compound: ADM	Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay	[PMID: 16499322]
HepG2	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27300257]
HepG2	GI₅₀	0.7 μM Compound: Dox	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HepG2	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22749279]
HepG2	IC₅₀	0.7 μM Compound: Dox	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
HepG2	IC₅₀	0.7 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay	[PMID: 30132670]
HepG2	IC₅₀	0.72 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 31926469]
HepG2	IC₅₀	0.72 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 30654238]
HepG2	IC₅₀	0.72 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26874404]
HepG2	IC₅₀	0.74 μM Compound: Dox	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 35339100]
HepG2	IC₅₀	0.74 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 25419616]
HepG2	CC₅₀	0.77 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay	[PMID: 32590115]
HepG2	IC₅₀	0.77 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 25537271]
HepG2	IC₅₀	0.79 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	10.1007/s00044-013-0777-z
HepG2	IC₅₀	0.79 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25078311]
HepG2	IC₅₀	0.79 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24836071]
HepG2	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 32324401]
HepG2	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 26586599]
HepG2	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 18547115]
HepG2	IC₅₀	0.87 μM Compound: AMD	Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 25812966]
HepG2	IC₅₀	0.877 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 24231309]
HepG2	IC₅₀	0.9 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by neutral red Cytotoxicity against human HepG2 cells after 48 hrs by neutral red	[PMID: 23891181]
HepG2	IC₅₀	0.9 μM Compound: Dox	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28704759]
HepG2	IC₅₀	0.919 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 34128674]
HepG2	IC₅₀	0.95 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	10.1039/C3MD00013C
HepG2	IC₅₀	0.954 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20832916]
HepG2	IC₅₀	0.99 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells by SRB assay Anticancer activity against human HepG2 cells by SRB assay	[PMID: 34128674]
HepG2	IC₅₀	1 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	[PMID: 21094049]
HepG2	IC₅₀	1 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32371335]
HepG2	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28919340]
HepG2	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32627543]
HepG2	IC₅₀	1 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay	[PMID: 24900509]
HepG2	IC₅₀	1.01 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
HepG2	IC₅₀	1.02 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23871222]
HepG2	IC₅₀	1.05 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells by MTT assay Anticancer activity against human HepG2 cells by MTT assay	[PMID: 25743216]
HepG2	IC₅₀	1.07 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 30719909]
HepG2	IC₅₀	1.08 μM Compound: Dox	Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay	10.1007/s00044-012-0057-3
HepG2	IC₅₀	1.1 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay	[PMID: 25096298]
HepG2	IC₅₀	1.12 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HepG2	IC₅₀	1.13 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by CCK8 assay Cytotoxicity against human HepG2 cells by CCK8 assay	[PMID: 29452840]
HepG2	IC₅₀	1.15 μM Compound: Adriamycin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24582982]
HepG2	IC₅₀	1.18 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis	[PMID: 32705864]
HepG2	IC₅₀	1.2 μM Compound: DOX	Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay	[PMID: 30746067]
HepG2	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay	10.1007/s00044-011-9884-x
HepG2	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27797185]
HepG2	IC₅₀	1.2 μM Compound: ADM	Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
HepG2	IC₅₀	1.2 μM Compound: ADM	Cytotoxicity against human Hep G2 by WST-8 assay Cytotoxicity against human Hep G2 by WST-8 assay	[PMID: 16933868]
HepG2	IC₅₀	1.2 μM Compound: adriamycin	Cytotoxicity against human HepG2 cells by rapid colorimetric assay Cytotoxicity against human HepG2 cells by rapid colorimetric assay	[PMID: 19585998]
HepG2	IC₅₀	1.21 μg/mL Compound: Doxorubicin	Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25042338]
HepG2	IC₅₀	1.21 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
HepG2	IC₅₀	1.22 μM Compound: adriamycin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26295905]
HepG2	IC₅₀	1.22 μM Compound: ADM	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 25089733]
HepG2	IC₅₀	1.3 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 34323485]
HepG2	IC₅₀	1.34 μM Compound: AMD	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26900656]
HepG2	IC₅₀	1.37 μM Compound: DOX	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 31057738]
HepG2	GI₅₀	1.4 μM Compound: Doxorubicin	Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
HepG2	IC₅₀	1.43 μM Compound: Doxorubicin	Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 30978023]
HepG2	IC₅₀	1.5 μM Compound: DOX	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28756264]
HepG2	IC₅₀	1.51 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
HepG2	IC₅₀	1.54 μM Compound: DOXO	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
HepG2	IC₅₀	1.54 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
HepG2	IC₅₀	1.54 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26963142]
HepG2	IC₅₀	1.6 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21708464]
HepG2	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 19583252]
HepG2	IC₅₀	1.61 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells after 48 hrs by MTT assay Anticancer activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25615796]
HepG2	IC₅₀	1.69 μM Compound: Dox	Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay	10.1007/s00044-012-0150-7
HepG2	IC₅₀	1.7 x 10^-1 μM Compound: doxorubicin	Growth inhibition of human HepG2 cells after 72 hrs by SRB assay Growth inhibition of human HepG2 cells after 72 hrs by SRB assay	[PMID: 18512984]
HepG2	IC₅₀	1.8 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
HepG2	IC₅₀	1.89 μM Compound: DOX	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 29509413]
HepG2	CC₅₀	1.95 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29792325]
HepG2	IC₅₀	1.969 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
HepG2	IC₅₀	10 nM Compound: Dox	Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31740054]
HepG2	IC₅₀	10 μM Compound: Doxorubicin	Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay	[PMID: 34128674]
HepG2	IC₅₀	10.15 μM Compound: Doxorubicin	Cytotoxicity activity against human HepG2 cells by MTT assay Cytotoxicity activity against human HepG2 cells by MTT assay	[PMID: 26873414]
HepG2	IC₅₀	10.4 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31323616]
HepG2	GI₅₀	10.7 μM Compound: DOX	Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 29316526]
HepG2	ED₅₀	102 μM Compound: doxorubicin	Antitumor activity against human HepG2 cells after 24 hrs by MTT assay Antitumor activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 17482824]
HepG2	IC₅₀	12.5 μM Compound: Adriamycin	Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24974349]
HepG2	IC₅₀	130 nM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 35213166]
HepG2	IC₅₀	14.7 μM Compound: Dox	Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay	[PMID: 31129455]
HepG2	IC₅₀	17.54 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21620529]
HepG2	IC₅₀	18.03 μM Compound: Dox	Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 33183865]
HepG2	IC₅₀	18.7 μM Compound: 12	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29852328]
HepG2	IC₅₀	19 nM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 21296467]
HepG2	IC₅₀	19 μg/mL Compound: doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay	10.1007/s00044-010-9436-9
HepG2	IC₅₀	2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay	10.1039/C3MD00097D
HepG2	IC₅₀	2.03 μM Compound: ADM	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 20932754]
HepG2	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 26821210]
HepG2	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29702447]
HepG2	IC₅₀	2.17 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay	[PMID: 21868138]
HepG2	IC₅₀	2.3 μM Compound: Doxorubicin	Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33439019]
HepG2	IC₅₀	2.32 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33352388]
HepG2	IC₅₀	2.35 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34124677]
HepG2	IC₅₀	2.41 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method	[PMID: 11473425]
HepG2	IC₅₀	2.41 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human HepG2 cells after 3 days Cytotoxicity against human HepG2 cells after 3 days	[PMID: 11975482]
HepG2	IC₅₀	2.5 mM Compound: Adriamycin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23685942]
HepG2	IC₅₀	2.5 mM Compound: Adriamycin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22440624]
HepG2	IC₅₀	2.5 nM Compound: Doxorubicin	Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA	[PMID: 24013411]
HepG2	IC₅₀	2.511 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28462842]
HepG2	IC₅₀	2.594 μM Compound: Doxorubicin	Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 27744185]
HepG2	IC₅₀	2.6 μM Compound: DOX	Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 30846253]
HepG2	IC₅₀	2.67 μM Compound: AMD	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 27639364]
HepG2	IC₅₀	2.68 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	10.1007/s00044-013-0795-x
HepG2	IC₅₀	2.7 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]

Doxorubicin (Synonyms: Hydroxydaunorubicin)

Other Forms of Doxorubicin:

Doxorubicin Related Antibodies

476 Publications Citing Use of MCE Doxorubicin

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

View All Topoisomerase Isoform Specific Products:

View All AMPK Isoform Specific Products:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review